

Yervoy

(ipilimumab, ENRs 2670877, 2670878)

Study CA184-020 / MDX10-20

Submission according to § 42b AMG

TABLE OF CONTENTS

1) SYNOPSIS

Full Title: A Randomized, Double-blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A*0201 Positive Patients with Previously Treated Unresectable Stage III or Stage IV Melanoma

Study Initiation Date: 14-Sep-2004

Study Completion Date: 07-Oct-2009

Report Date: Mar-2010

STATEMENT ON SIGNIFICANT CHANGES MADE SUBSEQUENTLY TO THE TRIAL PROTOCOL THAT ARE NOT COVERED IN THE REPORT ABOVE -

- there are no changes that are not covered in the synopsis

2) LIST OF INVESTIGATIONAL SITES that enrolled patients

127 sites have enrolled patients into this study and are therefore considered as "active". Sites that have not enrolled patients have been crossed out with a red line.

125 sites worldwide have treated patients - these sites are referred to in the synopsis: "a total of 676 subjects were randomized at 125 sites in Europe, North America, South America, and Africa."

Name of Sponsor/Company: Medarex, Inc. / Bristol-Myers Squibb	Individual Study Table Referring to the Dossier	(For National Authority Use Only)
Name of Finished Product: Ipilimumab		
Name of Active Ingredient: MDX-010		

SYNOPSIS

Clinical Study Report for Study MDX010-20

TITLE OF STUDY: A Randomized, Double-blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A*0201 Positive Patients with Previously Treated Unresectable Stage III or Stage IV Melanoma

INVESTIGATORS/STUDY CENTERS: Of the 1783 subjects who enrolled and were screened for study participation, a total of 676 subjects were randomized at 125 sites in Europe, North America, South America, and Africa.

PUBLICATIONS: None

STUDY PERIOD: Study Initiation Date: 27 September 2004
Last Patient First Visit: 24 July 2008
Study Completion Date: 7 October 2009

CLINICAL PHASE: 3

OBJECTIVES:

Primary Objective: To compare the overall survival (OS) of subjects administered ipilimumab (MDX-010; BMS-734016) in combination with gp100 melanoma peptide vaccine (MDX-1379, BMS-734019; the combination is herein referred to as ipilimumab plus gp100 and in tables as ipi+gp100) versus those administered ipilimumab placebo in combination with melanoma peptide vaccine (herein referred to as gp100 monotherapy and in tables as gp100).

Secondary Objectives:

- Comparison of OS of subjects administered ipilimumab plus gp100 to those administered ipilimumab in combination with vaccine placebo (herein referred to as ipilimumab monotherapy and in tables as ipi), and of subjects administered gp100 monotherapy vs. those administered ipilimumab monotherapy
- Determination of safety
- Evaluation of best overall response rate (BORR)
- Determination of major durable response rate
- Determination of duration of response
- Determination of progression-free survival (PFS)
- Determination of time-to-progression
- Evaluation of health-related Quality of Life (HRQoL)

METHODOLOGY: This was a Phase 3, randomized, double-blind, multicenter study in HLA-A*0201-positive (herein referred to as HLA-A2*0201-positive) subjects with a diagnosis of unresectable Stage III or Stage IV melanoma who had relapsed, failed, or were not able to tolerate at least 1 or more prior treatment regimens. In order to evenly balance factors that may influence outcome, subjects enrolled into the study were stratified on the basis of baseline TNM status (M0, M1a, or M1b vs. M1c) and prior treatment with interleukin-2 (IL-2).

The study consisted of 3 phases: Screening, Treatment, and Follow-up. Subjects who met the selection criteria were randomized in a double-blind fashion in a 3:1:1 ratio to receive ipilimumab plus gp100, ipilimumab monotherapy, or gp100 monotherapy. Ipilimumab or ipilimumab placebo was administered intravenously (IV) every 3 weeks for a total of 4 doses to the subjects in all 3 treatment groups. In addition, gp100 or vaccine placebo was administered by subcutaneous injection, immediately after administration of the ipilimumab dose. An induction cycle was defined as 4 doses of study medication administered 3 weeks apart. At the completion of the initial induction cycle, subjects entered the follow-up phase to be followed for response, survival, and safety.

Subjects who progressed following stable disease (of ≥ 3 months duration beginning at Week 12), or who had experienced an initial objective response (partial response [PR] or complete response [CR]) to the initial induction cycle could have been offered additional cycles of treatment with the originally assigned treatment regimen (re-induction) until off-treatment criteria were met, provided they continued to meet re-induction eligibility requirements. All adverse events (AEs) were to be reported through 70 days following the last dose of study treatment, or until adverse events resolved or stabilized; AEs occurring > 70 days following the last dose of study treatment and assessed by the investigator as probably or definitely related to study medication were also to be reported. No subject was to receive re-induction if they experienced a Grade ≥ 3 gastrointestinal or other selected immune-related adverse events (irAEs). No subject with disease progression following induction was permitted to receive re-induction with study medication.

All subjects who prematurely discontinued treatment due to a drug-related adverse event prior to Week 12 (in the absence of disease progression) were to return for all study visits and procedures including Week 12 and, if appropriate, further restaging assessments. Any subject with documented progression at any scheduled restaging visit who was not eligible for continued treatment was not required to have additional restaging assessments. Subjects with stable disease (SD), PR, or CR, who prematurely discontinued treatment due to a drug-related adverse event (AE) were to continue all study visits as per the protocol and have all study procedures performed.

Subjects who were not eligible or chose not to receive re-induction were to be followed for survival status by telephone every 3 months and were permitted to receive non-study antimelanoma medications at the discretion of the Investigator. All subjects randomized to the study were to be followed until at least 481 events (deaths) occurred in the study.

NUMBER OF SUBJECTS (Planned and Analyzed): The sample size was based on the primary objective, comparison of OS of ipilimumab plus gp100 and gp100 monotherapy. On the basis of a simulation using the collected blinded survival data from this study and historical literature data, a total of 385 events and a total of 500 enrolled subjects for the 2 groups would be expected to achieve a 90% power to detect a difference in OS between the 2 groups at the 0.05 significance level using the log-rank test.

A total of 676 subjects were randomized (403 subjects to ipilimumab plus gp100, 137 to ipilimumab monotherapy, and 136 to gp100 monotherapy) and included in the intent to treat (ITT) population; 643 subjects were treated (380 subjects with ipilimumab plus gp100, 131 to ipilimumab monotherapy, and 132 to gp100 monotherapy) and included in the safety, as treated population. One subject was randomized to ipilimumab plus gp100 but received a full induction cycle of treatment with gp100 monotherapy.

DIAGNOSIS AND MAIN CRITERIA FOR INCLUSION: HLA-A2*0201-positive subjects with a diagnosis of unresectable Stage III or Stage IV melanoma who, in response to 1 or more regimens

containing 1 or more of the following: IL-2, dacarbazine, temozolomide, fotemustine and/or carboplatin, had (1) relapsed following an objective response (PR/ CR); (2) failed to demonstrate an objective response (PR/CR); or (3) could not tolerate such a regimen due to unacceptable toxicity. All subjects must have received at least 1 course of first-line therapy.

TEST PRODUCT, DOSE AND MODE OF ADMINISTRATION, DURATION OF TREATMENT, BATCH NUMBERS: The 2 test product treatment groups were ipilimumab plus gp100 and ipilimumab monotherapy. Ipilimumab was administered at a dosage of 3 mg/kg as an intravenous (IV) infusion administered over 90 minutes every 3 weeks for a total of 4 doses, together with gp100 or matching vaccine placebo. Gp100 consisted of 2 separate peptide components: Peptide A, a peptide with sequence YLEPGPVTV (gp100:280-288[288V]) and Peptide B, a peptide with the sequence IMDQVPFSV (gp100:209-217[210M]). Each peptide was prepared with Montanide ISA-51. One dose of gp100 consisted of the administration of Peptide A, at a dosage of 2 mL or 2 mg, and Peptide B, at a dosage of 2 mL or 2 mg. The vaccine placebo consisted of sterile 0.9% sodium chloride. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy.

Relevant study drug components were administered from the following batches:

Ipilimumab: M31A-03-02FC, M31A-03-04FC, M31A-04-03FC, M31A-04-06FC, M31A-05-02FC, M31A-06-03FC

gp100 vaccine: MPS22-03-02FC, MPS22-05-01FC, MPS22-07-01FC, MPS21-05-01FC, MPS21-07-01FC, MPS21-03-02FC

gp100 placebo (vaccine placebo): Saline # 13-074-DK, Saline # 13-494-DK, and as of Amendment 2, the site was to supply saline to use as placebo and Medarex (MDX) supplied only the labels.

Montanide for subjects receiving gp100 vaccine: IFA-04-02FC, IFA-04-03FC, IFA-05-01FC, IFA-06-01FC

REFERENCE THERAPY, DOSE AND MODE OF ADMINISTRATION, DURATION OF TREATMENT, BATCH NUMBERS: The reference therapy group for this study was gp100 monotherapy. One dose of gp100 consisted of the administration of Peptide A, at a dosage of 2 mL or 2 mg, and Peptide B, at a dosage of 2 mL or 2 mg. Each peptide was prepared with Montanide ISA-51. Gp100 was administered every 3 weeks together with matching ipilimumab placebo, administered as an IV infusion. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy (matching ipilimumab placebo plus gp100).

Relevant study drug components were administered from the following batches:

Ipilimumab Placebo: PLCB-04-01FC, PLCB-07-01FC

gp100 vaccine: MPS22-03-02FC, MPS22-05-01FC, MPS22-07-01FC, MPS21-05-01FC, MPS21-07-01FC, MPS21-03-02FC

Montanide for subjects receiving gp100 vaccine: IFA-04-02FC, IFA-04-03FC, IFA-05-01FC, IFA-06-01FC

CRITERIA FOR EVALUATION:

Efficacy: The primary efficacy endpoint was the comparison of OS for subjects administered ipilimumab plus gp100 versus those administered gp100 monotherapy. Secondary efficacy endpoints included comparison of OS for subjects administered ipilimumab plus gp100 vs. those administered ipilimumab monotherapy, and for subjects administered gp100 monotherapy vs. those administered ipilimumab monotherapy. Other secondary endpoints were based on investigator reported response (no IRC review) and included: BORR up to Week 24 (as determined by site Investigator tumor response assessment based on modified WHO criteria), duration of response, PFS, and time-to-progression. The European

Organization for Research and treatment of Cancer (EORTC) QLQ-C30 questionnaire was the primary instrument used to measure QOL.

Safety: Safety was evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. The key safety endpoints were: deaths, the incidence of on-study AEs, particularly irAEs, discontinuation due to AEs, clinical laboratory tests, physical examinations, and vital sign measurements. An independent Data Monitoring Committee (DMC) monitored safety and made recommendations on study continuation or modification to the Sponsor Steering Committee.

STATISTICAL CONSIDERATIONS: The original sample size of 750 subjects was based on a primary endpoint of BORR, comparing the combination group to each of the 2 monotherapy groups. Subsequently, the primary endpoint was amended to be OS and the protocol design was amended to have a single primary comparison of ipilimumab plus gp100 and gp100 monotherapy. The change in the primary endpoint was made for 2 reasons. First, previous Health Authority advice had included a recommendation to use overall survival as the primary endpoint for this study. Second, as the Phase 2 data matured, it became clear that the survival endpoint more accurately captures the clinical benefit of ipilimumab than do conventional tumor response endpoints. The use of BORR were designed to capture the benefit of conventional chemotherapy where progressive disease by the standard criteria is never expected to be followed by durable tumor suppression and/or objective response, whereas the biology of immunotherapy is substantially different as has been described in subjects treated with immunotherapies. Since validated endpoints that reflect the mechanisms underlying immunotherapy are not yet available, the gold-standard endpoint of overall survival becomes the most appropriate measure for assessing the clinical efficacy and safety of ipilimumab.

The sample size was revised based on the new primary comparison, OS of ipilimumab plus gp100 and gp100 monotherapy. On the basis of a simulation using the collected blinded survival data from this study and historical literature data, a total of 385 events and a total of 500 enrolled subjects for the 2 groups (ipilimumab plus gp100 and gp100 monotherapy) were required to achieve a 90% power to detect a difference in OS between the 2 groups at the 0.05 significance level using the log-rank test. Therefore, a total of 481 events were required in all 3 groups (assuming that the events are distributed with ratios at 3:1:1 in ipilimumab plus gp100, ipilimumab monotherapy, and gp100 monotherapy, respectively). On the basis of these assumptions, and with study enrollment over 650 subjects, enrollment into the study was closed effective 25 July 2008. The observed 219 events out of 273 subjects randomized in a 1:1 ratio (ipilimumab monotherapy vs. gp100) yields at least 80% power with a two-sided alpha of 0.05.

For the primary efficacy analysis, the difference in OS between ipilimumab plus gp100 vs. gp100 monotherapy was compared using stratified log-rank test along with the depiction of the Kaplan-Meier survival curve. The 2 stratification factors were baseline TNM status (M0, M1a, or M1b versus M1c), and prior or no prior treatment with IL-2. The median estimates with 95% confidence intervals (CIs) were computed using Brookmeyer and Crowley method. The other time-to-event parameters (PFS and time-to-progression) were also analyzed using the same methods as for OS.

The secondary efficacy analysis of survival compared the OS of ipilimumab monotherapy to gp100 monotherapy and ipilimumab plus gp100 to ipilimumab monotherapy. Treatment differences for the BORR (as determined by site Investigator up to Week 24 and confirmed at least 4 weeks later) were compared using the stratified CMH test. The duration of response was summarized by treatment group using descriptive statistics for responder subjects only. The HRQoL was compared for treatment differences using an Analysis of Covariance (ANCOVA) model.

Safety parameters were summarized using descriptive statistics (frequency tabulation), including the following items: any AE, any serious AE (SAE), any study drug related AE, any irAE, death, and discontinuation of study medication due to AE. Routine clinical laboratory findings were summarized using descriptive statistics for each treatment group. Changes from baseline to each visit were determined for quantitative variables.

SUMMARY OF RESULTS:

Disposition and Baseline/Demographic Characteristics:

Of the 1783 subjects who enrolled and were screened for study participation, a total of 676 subjects were randomized between 27-Sep-2004 and 24-July-2008: 403 to ipilimumab plus gp100, 137 to ipilimumab monotherapy, and 136 to gp100 monotherapy. **Table 1** presents subject disposition according to randomized treatment assignment; however, 1 subject was randomized to ipilimumab plus gp100 but treated with gp100 monotherapy. This subject is counted in the ipilimumab plus gp100 group for baseline characteristics and efficacy analyses, and in the gp100 monotherapy group for dosing and safety analyses.

Table 1: Subject Disposition

	Ipi+gp100	Ipi	gp100	Total
Enrolled	-	-	-	1783
Randomized	403 (100.0)	137 (100.0)	136 (100.0)	676 (100.0)
Not Treated	22 (5.5)	6 (4.4)	5 (3.7)	33 (4.9)
Treated ^a	381 (94.5)	131 (95.6)	131 (96.3)	643 (95.1)
Discontinued Study ^b				
Death (all causes)	306 (75.9)	100 (73.0)	119 (87.5)	525 (77.7)
Subject withdrew consent	10 (2.5)	2 (1.5)	3 (2.2)	15 (2.2)
Other ^c	3 (0.7)	3 (2.2)	2 (1.5)	8 (1.2)
Lost to follow-up	3 (0.7)	2 (1.5)	1 (0.7)	6 (0.9)
Protocol violation	0	0	1 (0.7)	1 (0.1)
Trial completed	81 (20.1)	30 (21.9)	10 (7.4)	121 (17.9)

^a Data are presented based on randomization; however, 1 subject was randomized to Ipi+gp100 but treated with gp100. Therefore dosing and safety analyses will count this subject in the gp100 treatment group.

^b Percentage based on all randomized subjects

^c Reasons for study discontinuation for 2 subjects under 'Other' were study completion (ipi + gp100) and overall study closed (ipi), respectively; these subjects should have been included under Trial completed.

The median age of subjects was 57 years, and a majority (59%) was male. Over 90% of subjects were white, and 98% had Stage IV disease. The majority of subjects were M1c stage (71.4%) and approximately one-third of subjects had an elevated LDH at baseline. The 3 treatment groups were well balanced for demographic characteristics, including baseline M-stage at randomization and prior IL-2 use, as would be expected since these were stratification factors contributing to the randomization (**Table 2**). ECOG performance status was 0 or 1 for all but 1 subject whose status was unknown.

Table 2: Demographic and Baseline Characteristics (ITT Population)

Characteristic	Ipi+gp100 n=403	Ipi n=137	gp100 n=136	Total n=676
Age (years)				
Mean	55.6	56.8	57.4	56.2
Median	57.0	57.0	57.0	57.0
Sex (n %)				
Male	247 (61)	81 (59)	73 (54)	401 (59)
Female	156 (39)	56 (41)	63 (46)	275 (41)
Race (n %)				
White	380 (94.3)	129 (94.2)	129 (94.9)	638 (94.4)
Black	3 (0.7)	1 (0.7)	1 (0.7)	5 (0.7)
Hispanic	18 (4.5)	7 (5.1)	5 (3.7)	30 (4.4)
Other	2 (0.5)	0	1 (0.7)	3 (0.4)
M Stage				
M0	5 (1.2)	1 (0.7)	4 (2.9)	10 (1.5)
M1a	37 (9.2)	14 (10.2)	11 (8.1)	62 (9.2)
M1b	76 (18.9)	22 (16.1)	23 (16.9)	121 (17.9)
M1c	285 (70.7)	100 (73.0)	98 (72.1)	483 (71.4)
Prior IL-2				
No	315 (78.2)	105 (76.6)	103 (75.7)	523 (77.4)
Yes	88 (21.8)	32 (23.4)	33 (24.3)	153 (22.6)
LDH				
>ULN	148 (36.7)	53 (38.7)	54 (39.7)	255 (37.7)
≤ULN	255 (63.3)	84 (61.3)	82 (60.3)	421 (62.3)

ULN = upper limit of normal; Min = minimum; Max = maximum

Exposure: Most subjects (603/643; 94%) were treated only during the induction cycle of treatment; forty (40) subjects (6%) received re-induction. Four-hundred eight (408) subjects (63.5%) received the target number of doses of ipilimumab/ipilimumab placebo and 406 subjects (63.1%) received the target number of doses of gp100/vaccine placebo.

Efficacy Results:

Overall Survival Survival follow-up was current (defined as having died or last known alive date occurring on or after the 19-June-2009 cutoff) for 83% of subjects, while 4% of subjects had a last known alive date that was obtained more than 3 months before the cutoff for follow-up. Median follow-up for alive subjects was 21 months for the ipilimumab plus gp100 group, 28 months for the ipilimumab monotherapy group, and 17 months for the gp100 monotherapy groups. Subjects known to be alive were followed for as long as 55 months.

The primary objective of this study was the comparison of OS in subjects administered ipilimumab plus gp100 versus gp100 monotherapy. The hazard ratio (HR) for comparison of OS between the ipilimumab plus gp100 and gp100 monotherapy groups was 0.68 (95% CI: 0.55, 0.85; $p = 0.0004$) (**Table 3**), indicating a 32% risk reduction in OS for the ipilimumab plus gp100 group compared with the gp100 monotherapy group. The HR for comparison of OS between the ipilimumab monotherapy and gp100 monotherapy groups was 0.66 (95% CI: 0.51, 0.87; $p = 0.0026$), indicating a 34% risk reduction in OS for the ipilimumab monotherapy group compared with the gp100 group. The HR for comparison of OS between the ipilimumab plus gp100 and ipilimumab monotherapy groups was 1.04 (95% CI: 0.83, 1.30; $p = 0.7575$) demonstrating no difference in survival outcomes between both groups.


Table 3: Overall Survival by Treatment (ITT Population)

	Ipi+gp100 (n=403)	Ipi (n=137)	gp100 (n=136)	Total (n=676)
Number of events	306	100	119	525
HR vs.gp100 with 95% CI	0.68 (0.55, 0.85)	0.66 (0.51, 0.87)		
Log-rank p value vs. gp100	0.0004	0.0026		
HR vs. Ipilimumab with 95% CI	1.04 (0.83, 1.30)			
Log-rank p value vs. Ipilimumab	0.7575			

The Kaplan-Meier survival curves are similar for the 3 treatment groups through approximately the first 4 months of treatment (**Figure 1**), after which a separation in the curves suggests a favorable OS advantage for the ipilimumab plus gp100 and ipilimumab monotherapy groups compared with the gp100 group.

Median OS was 9.95 months (95% CI: 8.48, 11.50) in the ipilimumab plus gp100 group, 10.12 months (95% CI: 8.02, 13.80) in the ipilimumab monotherapy group, and 6.44 months (95% CI: 5.49, 8.71) in the gp100 monotherapy group.

Figure 1: Overall Survival by Treatment (ITT Population)



/wwwbdm/clin/proj/ca/184/iss01/val/stats/adhoc/64_os_plot.sas

RUN DATE: 16-Mar-2010 8:03

The estimated 1-year and 2-year survival rates were consistently higher in the ipilimumab-treated groups. The estimated 1-year survival rates were 43.6% in the ipilimumab plus gp100 group, 45.6% in the ipilimumab monotherapy group, and 25.3% in the gp100 group. The estimated 2-year survival rates were 21.6%, 23.5%, and 13.7%, respectively. Long-term survival (at least 2 years) was observed for ipilimumab + gp100 and ipilimumab monotherapy groups with 54 and 24 subjects, respectively, alive for at least 2 years, compared with 16 subjects in the gp100 group.

Subgroup comparisons for OS were performed across 5 pre-specified categories: M-stage (M0, M1a or M1b versus M1c), prior IL-2, baseline LDH ($\leq$ ULN versus $>$ ULN), age ($<$ 65 years versus $\geq$ 65 years), and gender. The subgroup categories of M-stages, prior IL-2 and baseline LDH represent prognostic factors affecting outcome in late stage melanoma. In addition, prior IL-2 treatment and M-stage were used as stratification factors for randomization in this study. The results from the subgroup analyses demonstrate a consistent pattern with HRs favoring either of the ipilimumab-treated groups relative to the gp100 monotherapy group. Subgroup analyses for ipilimumab plus gp100 versus ipilimumab monotherapy consistently showed HRs whose 95% CIs overlap 1, indicating comparable activity across the 2

ipilimumab-treated groups. These pre-specified analyses demonstrate that the performance of ipilimumab within relevant prognostic subgroups is highly consistent with the survival advantage that was demonstrated for the overall study population.

BORR, Disease Control Rate (DCR), PFS, PFS Rate, duration of response, time to progression (TTP)

Secondary endpoints of BORR, DCR, PFS, PFSR, duration of response, time-to-progression are summarized (**Table 4**). The responses observed with ipilimumab treatment were durable. Among the subjects in the ipilimumab-treated groups that achieved an objective response; response was maintained for at least 2 years for 60.0% (9/15) of subjects treated with ipilimumab monotherapy (range: 26.5+ to 44.2+ months) and 17.4% (4/23) of subjects treated with ipilimumab plus gp100 (range: 27.9+ to 44.4+). Of these, 3 subjects maintained their response for more than 36 months. None of the subjects treated with gp100 remained in response at the 2-year time point.

Table 4: MDX010-20 - Secondary Efficacy Endpoints (ITT Population)

	Ipi + gp100 n = 403	Ipi n = 137	gp100 n = 136
BORR (CR and PR)			
n (%)	23 (5.7)	15 (10.9)	2 (1.5)
95% CI	(3.7, 8.4)	(6.3, 17.4)	(0.2, 5.2)
Treatment comparison - BORR	p-value ^a		
Ipi + gp100 vs. gp100	0.0433		
Ipi vs. gp100	0.0012		
Ipi + gp100 vs. Ipi	0.0402		
DCR (CR, PR, SD)			
n (%)	81 (20.1)	39 (28.5)	15 (11.0)
95% CI	(16.3, 24.3)	(21.1, 36.8)	(6.3, 17.5)
BOR, N (%)			
CR	1 (0.2)	2 (1.5)	0
PR	22 (5.5)	13 (9.5)	2 (1.5)
SD	58 (14.4)	24 (17.5)	13 (9.6)
PD	239 (59.3)	70 (51.1)	89 (65.4)
Not evaluated	83 (20.6)	28 (20.4)	32 (23.5)

Table 4: MDX010-20 - Secondary Efficacy Endpoints (ITT Population)

	Ipi + gp100 n = 403	Ipi n = 137	gp100 n = 136
PFS (months)			
Median (95% CI)	2.76 (2.73, 2.79)	2.86 (2.76, 3.02)	2.76 (2.73, 2.83)
Treatment comparison - PFS	Hazard Ratio (95% CI) ^b		
Ipi + gp100 vs. gp100	0.81 (0.66, 1.00)		
Ipi vs. gp100	0.64 (0.50, 0.83)		
Ipi + gp100 vs. Ipi	1.25 (1.01, 1.53)		
Time to Progression (months)			
Median (95% CI)	2.76 (2.73, 2.79)	2.86 (2.76, 3.02)	2.76 (2.73, 2.83)
Time to Response (months)			
N	23	15	2
Mean (95% CI)	3.324 (2.991, 3.737)	3.176 (2.753, 3.598)	2.743 (2.117, 3.370)
Duration of Response (months)			
N	23	15	2
Median (95% CI)	11.47 (5.36, NR)	NR (28.09, NR)	NR (2.00, NR)

BORR = best overall response rate, BOR = best overall response, DCR = disease control rate, PFS = progression free survival, CI = confidence interval, CR = confirmed complete response, PR = confirmed partial response, SD = stable disease, PD = progressive disease, NE = not evaluated, missing, or unknown, NR = not reached

95% confidence intervals (CI) for median were computed using Brookmeyer and Crowley method.

^a The comparison for P-values was performed between ipi + gp100 vs. gp100, ipi vs. gp100, and ipi+gp100 vs. ipi. P-values were computed using CMH test stratified by baseline M-stage at randomization (M0, M1a, M1b vs. M1c) and prior IL-2 treatment (Yes vs. No).

^b Cox model for Hazard ratios (HR) and log-rank test p-values were stratified by baseline M-stage at randomization (M0, M1a, M1b vs. M1c) and prior treatment IL-2 with (Yes vs. No).

Safety Results: Safety results are characterized based on the entire study duration unless otherwise specified. Progressive disease was the most frequent reason of death across treatment groups. Adverse events with an outcome of death were reported for 44 subjects, of which 14 were judged by the Investigator to be related to study drug: 8 (2.1%) subjects in the ipilimumab plus gp100, 4 (3.1%) in the ipilimumab monotherapy and 2 (1.6%) in the gp100 monotherapy groups (Table 5). On-study AEs, severe AEs (≥ Grade 3), and SAEs were reported in a similar proportion of subjects across treatment groups. Study drug-related AEs (ie, related to either ipilimumab or gp100), were reported for 85.4% of subjects, and were ≥ Grade 3 for 19.3% of subjects.

The most frequently reported drug-related AEs were irAEs. Immune-related AEs (any grade) were reported for 53.3% of subjects and were ≥ Grade 3 for 10.7% of subjects (Table 5). The proportion of subjects with

irAEs was higher in the ipilimumab-treated groups, compared to gp100 monotherapy. Across treatment groups, the most frequently ($\geq 2\%$) reported irAEs were skin and subcutaneous tissue disorders and gastrointestinal (GI) disorders and, less commonly, hepatic and endocrine disorders. The most frequently ($\geq 5\%$) reported GI irAE were diarrhea and colitis. Intestinal perforation (including large intestine perforation) occurred in 5 subjects in the ipilimumab plus gp100 group and 1 subject in the ipilimumab monotherapy group. The most frequently reported skin irAEs were rash (including pruritic and generalized rash), pruritus (including generalized pruritus) and urticaria. Toxic epidermal necrolysis occurred in 1 subject in the ipilimumab plus gp100 group. The most frequently reported endocrine irAEs were hypothyroidism and hypopituitarism. Liver irAEs were infrequent in all 3 treatment groups with the highest rate of events (4.5% for all grades and 2.3% for $\geq$ Grade 3) in the gp100 monotherapy group. Hepatic failure (Grade 5) occurred in 1 subject in the ipilimumab monotherapy group.

Table 5: Summary of On-Study Safety (Safety Population)

	Ipi+gp100 (n=380)	Ipi (n=131)	gp100 (n=132)	Total (n=643)
Subjects with any on-study AE ^a (n %)	374 (98.4)	127 (96.9)	128 (97.0)	629 (97.8)
Severe ($\geq$ Grade 3)	194 (51.1)	73 (55.7)	69 (52.3)	336 (52.3)
Serious	156 (41.1)	56 (42.7)	52 (39.4)	264 (41.1)
Related	339 (89.2)	106 (80.9)	104 (78.8)	549 (85.4)
AEs leading to study drug discontinuation	35 (9.2)	17 (13.0)	5 (3.8)	57 (8.9)
AE with outcome of death (n%)	23 (6.1)	13 (9.9)	8 (6.1)	44 (6.8)
Related AE with outcome of death	8 (2.1)	4 (3.1)	2 (1.6)	14 (2.2)
Immune Related Adverse Events (irAE)^b				
Subjects with any irAE (n %)	220 (57.7)	81 (61.8)	42 (32.1)	343 (53.3)
Severe ($\geq$ Grade 3) irAE	44 (11.6)	21 (16.0)	4 (3.0)	69 (10.7)
Serious irAE	41 (10.8)	18 (13.7)	1 (0.8)	60 (9.3)
irAE leading to study drug discontinuation	22 (5.8)	11 (8.4)	1 (0.8)	34 (5.3)
Death due to irAE (n %)	4 (1.1)	2 (1.5)	0	6 (0.9)
Gastrointestinal irAEs (any grade)	122 (32.1)	39 (29.8)	19 (14.4)	180 (28.0)
Severe ($\geq$ Grade 3)	25 (6.6)	11 (8.4)	1 (0.8)	37 (5.8)
Hepatic irAEs (any grade)	8 (2.1)	5 (3.8)	6 (4.5)	19 (3.0)
Severe ($\geq$ Grade 3)	4 (1.1)	1 (0.8)	3 (2.3)	8 (1.2)
Endocrine irAEs (any grade)	16 (4.2)	10 (7.6)	2 (1.5)	28 (4.4)
Severe ($\geq$ Grade 3)	4 (1.1)	5 (3.8)	0	9 (1.4)
Skin irAEs (any grade)	152 (40.0)	56 (42.7)	25 (18.9)	233 (36.2)
Severe ($\geq$ Grade 3)	9 (2.4)	2 (1.5)	0	11 (1.7)

Table 5: Summary of On-Study Safety (Safety Population)

	Ipi+gp100 (n=380)	Ipi (n=131)	gp100 (n=132)	Total (n=643)
Other ^c irAEs (any grade)	15 (3.9)	6 (4.6)	3 (2.3)	24 (3.7)
Severe (≥ Grade 3)	8 (2.1)	3 (2.3)	1 (0.8)	12 (1.9)

AE = adverse event, irAE = immune-related adverse event

^a On-study AEs are AEs reported after the first dose that occurred within 70 days of the last dose or any AE related to the study drug.

^b irAEs are adverse events of unknown etiology associated with study drug exposure and consistent with an immune phenomenon that were reported by the Investigator to be possibly, probably, or definitely related to study drug or with unknown causality.

^c Includes blood, eye, immune system, infections, renal and respiratory system.

Re-induction: A total of 40 subjects were exposed to at least 1 cycle of re-induction. Of these, 32 were evaluated for efficacy. The disease control rate in the ipilimumab-treated groups was 65% to 75% compared to 0% in the gp100 monotherapy group upon re-induction. The safety profile was similar to that seen for the duration of the study. Drug-related AEs were reported in 25 (86.2%), 7 (77.8%), and 2 (100%) subjects in the ipilimumab plus gp100, ipilimumab monotherapy, and gp100 monotherapy groups, respectively. The most common drug-related AEs reported during re-induction were AEs affecting the GI tract and skin in the ipilimumab-treated groups and injection site reactions in gp100-treated groups. Immune-related AEs were reported in 15 (51.7%), 7 (77.8%), and 1 (50%) subjects in the ipilimumab plus gp100, ipilimumab monotherapy, and gp100 monotherapy groups, respectively. The most common irAEs reported during re-induction were irAEs affecting the skin and GI tract. In nearly all cases, irAEs were Grade 1-2 in severity.

Quality of Life: Most changes from baseline in HRQoL domains were “no change” to “moderate” across the three treatment groups. The trend in global health status was towards return to baseline. There was no difference between treatment groups.

CONCLUSIONS:

- Ipilimumab reduced the risk of death from melanoma by 32% to 34% (hazard ratios of 0.68 [95% CI: 0.55, 0.85; p=0.0004] and 0.66 [95% CI: 0.51, 0.87; p=0.0026] for the 2 comparisons of ipilimumab vs. gp100)
- There was no difference in OS between the ipilimumab monotherapy and ipilimumab plus gp100 groups.
- Ipilimumab demonstrated a consistent survival benefit across prognostic factor subsets, including M stage, LDH, prior IL-2 therapy, age, and sex.
- Long-term survival (up to 2 years) and durable responses are observed.
- Statistically significant results in favor of ipilimumab-treated groups were observed for other efficacy endpoints (BORR, DCR, and PFS).
- Adverse events are expected in this population with late stage melanoma; irAEs reflect the immune-mediated mechanism of action of ipilimumab and occur frequently (any irAE in 60% of subjects treated with an ipilimumab-containing regimen; ≥ Grade 3 events in 12-16%).

- Rates for subcategories of irAEs vary by the organ system involved, with skin and GI events occurring more frequently than endocrine, hepatic and other events.
- The temporal onset of irAEs also varies by the organ system involved; median time to onset of Grade 2-5 skin irAEs was 3-4 weeks and Grade 2-5 GI irAEs was 6-9 weeks.
- The use of steroids or alternate immunosuppression can reverse the irAE-associated inflammatory process. Overall, systemic steroid use occurred in 37% of subject in both ipilimumab containing groups and in 28% of the gp100 group. In this study the observed time to resolution was 4-5 weeks for Grade 2-4 skin irAEs and 3-4 weeks for Grade 3-4 GI irAEs.
- AEs leading to study drug discontinuation occurred more frequently with ipilimumab treatment (9.2%-13% versus 3.8% for gp100); the majority of the discontinuations in the 2 ipilimumab-containing arms were due to irAEs.
- Drug-related deaths were reported in 8 (2.1%) subjects treated with ipilimumab plus gp100, 4 (3.1%) ipilimumab monotherapy and 2 (1.6%) gp100 monotherapy. A subset of 6 drug-related deaths occurred as a consequence of an irAE (4 GI irAEs in the ipilimumab plus gp100 group; 1 GI irAE and 1 hepatic irAE in the ipilimumab monotherapy group); 1 additional drug-related death (ipilimumab plus gp100) from Guillain-Barre Syndrome is considered an irAE-associated death.
- Re-induction treatment was followed by additional objective responses or stable disease and the safety profile for re-induction was consistent with the overall safety profile for ipilimumab.
- The findings showing “no change” to “a little” decline in HRQoL after treatment with ipilimumab plus gp100 or ipilimumab monotherapy over 12 weeks in this advanced stage melanoma population suggest that ipilimumab is well tolerated in the induction phase. Further research is required to determine long-term HRQoL in patients with advanced stage melanoma.

DATE OF REPORT: Mar-2010

Appendix A.5: List of Investigators

Protocol MDX010-20
66 page(s) excluding cover page

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
001	O'Day, Stephen, MD	The Angeles Clinic and Research Institute 11818 Wilshire Boulevard, Suite 200 Los Angeles, CA 90025 United States of America	Boasberg, Peter, MD Dorff, Tanya, MD Hamid, Omid, MD Ledezma, Blanca, NP Lieber, Daniel, MD Piro, Lawrence, MD Shaum, Melani, MD	28
002	Tchekmedyian, N. Simon, MD	Pacific Shores Medical Group 1043 Elm Avenue, Suite 104 Long Beach, CA 90813 United States of America	Hok, Dina, PA-C Liem, Andre, MD Quan, Eleonor, MD Ray, Chona, NP Wang, Amy Qiu, MD Wu, Lihong, MD	1

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
003	Chow, Warren, MD Margolin, Kim, MD	City of Hope 1500 East Duarte Road Duarte, CA 91010 United States of America	Chow, Warren, MD Koczyws, Marianna, MD Koehler, Stephen, MD Leong, Lucille, MD Lim, Dean, MD Luu, Thehang, MD Martel, Cynthia, MD McNamara, Mark, MD Morgan, Robert, MD Polonsky, Monty, MD Portnow, Jana, MD Shibata, Stephen, MD Somlo, George, MD Twardowski, Przemyslaw, MD Yen, Yun, MD	3
004	Weber, Robert, MD	Northern California Melanoma Center St. Mary's Medical Center 450 Stanyan Street, Sixth Floor San Francisco, CA 94117 United States of America	Marlin, Ruth, MD Minor, David, MD Rose, Madalene, RN Spitler, Lynn, MD Trautvetter, Sharon, RN	24
006	Gitlitz, Barbara, MD Weber, Jeffrey, MD, PhD	USC/Norris Cancer Center Room 3452 1441 Eastlake Avenue Los Angeles, CA 90033 United States of America	Weber, Jeffrey, MD, PhD	4

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
007	Adler, Mark, MD McClay, Edward, MD	San Diego Cancer Center 910 Sycamore Avenue, Suite 102 Vista, CA 92081 United States of America	Bessudo, Alberto, MD Eisenberg, Steven, DO Frakes, Laurie, MD Lewis, Chris, PA McClay, Edward, MD Subramanian, Rupa, MD Vicaro, Daniel, MD	2
017	Paroly, Warren, MD Just, Richard, MD	Scripps Cancer Center 11025 North Torrey Pines Road, Suite 200 La Jolla, CA 92037 United States of America	Bernstein, Joel I., MD Eisenberg, Steven, DO Hampshire, Andrew P., MD Johnson, Kenneth B., MD Kosty, Michael P., MD Kroener, Joan F., MD McClay, Edward, MD Mason, James R., MD Norton, Marilyn S., MD Oblon, David J., MD Paroly, Warren, MD Reissmann, Peter T., MD Siddique, Nayyar, MD Sinclair, James M., MD Wallach, Sabina R., MD	3

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
~~031~~	~~Ebrahimi, Behnam, MD~~	Wilshire Oncology Medical Group, Inc 1502 Arrow Highway LaVerne, CA 91750 United States of America	Allen, Carla, MSN, APRN, BC, OCN Bosserman, Linda D., MD Horns, Richard, C. Jr., MD Howard, Frank, D. IV, MD Parker, Marjorie A., MD Presant, Cary A., MD Upadhyaya, Gargi H., MD Vakil, Mayank J., MD Yeon, Christina H., MD Young, Traci, MSN, RN, ONP	~~0~~
~~032~~	~~Ho, Winston, MD~~	St. Joseph Hospital, Orange 1140 West La Veta Avenue, Suite 610 Orange, CA 92868 United States of America	Byun, Timothy, MD ~~Charney, Kim, MD~~ Wong, Siu-Fun, PharmD.	~~0~~
~~035~~	~~Gailani, Fawaz, MD~~	Kaiser Permanente 10800 Magnolia Avenue # 4E Riverside, CA 92505 United States of America	None	~~0~~
036	Daniels, Gregory, MD	University of California, San Diego 3855 Health Sciences Drive La Jolla, CA 92093-0987 United States of America	Heichel, Christopher, MD Read, William, MD Vemuri, Swarajya Lakshmi, MD	3

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
~~051~~	~~Feun, Lynn, MD~~	~~University of Miami/Sylvester Comprehensive Cancer Center 1475 NW 12th Avenue Miami, FL 33136 United States of America~~	~~Elgart, George, MD Hurley, Judith, MD~~	~~0~~
~~052~~	~~Hussein, Atif, MD~~	~~Memorial Cancer Institute 1150 North 35th Avenue, Suite 170 Hollywood, FL 33021 United States of America~~	~~Abraham, Anna, MD Cano, Roberto, MD Cohen, James, MD Domenech, Gabriel, MD Feinstein, Lyle, MD Forsythe, Patricia, ARNP Franco, Sandra, MD Glasser, Robert, MD Grosman, Daren, MD Lewis, Mark, MD Mudad, Raja, MD Perez, Alejandra, MD Restrepo, Maria, MD~~	~~0~~
054	Lutzky, Jose, MD	Mount Sinai Comprehensive Cancer Center 4306 Alton Road Miami Beach, FL 33140 United States of America	Blaustein, Arnold, MD Cusnir, Mike, MD Davila, Enrique, MD Dominguez, Carlos, MD Krill, Elisa, MD Lilenbaum, Rogerio, MD Pizzolato, Joseph, MD Schwartz, Michael, MD	12

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
~~055~~	~~Pennock, Gregory K., MD~~	M.D. Anderson Cancer Center Orlando 1400 South Orange Avenue MP#780 Orlando, FL 32806 United States of America	Hajdenberg, Julio, MD Kayaleh, Omar R., MD ~~Sanjiv, Jose E., MD~~ Shah, Nikita C., MD Tseng, Jennifer E., MD	~~0~~
057	Rothschild, Neal, MD	Palm Beach Cancer Institute 1309 North Flagler Drive West Palm Beach, FL 33401 United States of America	Ahr, David, MD Gersten, Todd, MD Green, Robert, MD Harris, James, MD Jacobson, Robert, MD McKeen, Elisabeth, MD Raymond, Marilyn, MD Schwartz, Augustin III, MD Smukler, Avram, MD Spitz, Daniel, MD Tolnai, Edit, MD	1
~~058~~	~~Reintgen, Douglas, MD~~	Lakeland Regional Cancer Center 3525 Lakeland Hills Boulevard Lakeland, FL 33805 United States of America	Cassell, Robert, MD ~~Jakub, James, MD~~ Pendas, Solange, MD	~~0~~

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
059	Pham, Dat, MD Guthrie, Troy H. Jr., MD	University of Florida College of Medicine at Jacksonville 655 West 8th Street Pavilion 4 North Jacksonville, FL 32209 United States of America University of Florida College of Medicine at Jacksonville 555 West 8th Street 4th North Pavilion Jacksonville, FL 32209 United States of America	Chingos, James, MD Mignone, Joseph, MD Pham, Dat, MD Rana, Fauzia, MD Villegas, Augusto E., MD Walker, Ru-Amir, MD	1
~~060~~	~~Kaywin, Paul, MD~~	~~Advanced Medical Specialties 8940 North Kendall Drive, Suite 300E Miami, FL 33176 United States of America~~	~~Albrecht, Federico, MD Behrmann, Frances A., MD Citron, Peter L., MD de Zarraga, Fernando, MD Feinberg, Alan D., MD Garrido, Sara M., MD Kalman, Leonard A., MD Larcada, Alberto F., MD Muina, Antonio F., MD Spektor, Frank, MD Troner, Michael B., MD Ucar, Antonio, MD Venkatappa, Siddharta, MD Wallach, Howard W., MD Wang, Grace, MD~~	~~0~~

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
061	Wolchok, Jedd, MD	Memorial Sloan Kettering Cancer Center 1275 York Avenue New York, NY 10021 United States of America	Carvajal, Richard, MD Chapman, Paul, MD Ejadi, Samuel, MD Houghton, Alan, MD Krown, Susan, MD Livingston, Philip, MD Schwartz, Gary, MD	9
062	Kaufman, Howard L., MD	Columbia University Medical Center 177 Fort Washington Avenue MHB-7SK New York, NY 10032 United States of America	Barile, Gaetano, MD Taback, Bret, MD Sherman, William, MD	7
064	Kirshner, Jeffrey J., MD	Hematology-Oncology Associates of CNY 5008 Brittonfield Parkway, Suite 700 PO Box 2050 East Syracuse, NY 13057-2050 United States of America	Bingham, M. Daniel, MD Cherny, Richard C., MD Churchill, David A., MD DiFino, Santo M., MD Gullo, John J., MD Kligerman, Olga, DO Maher, Thomas J., MD Navone, Joseph M., MD Puc, Heidi S., MD Scalzo, Anthony J., MD Wong, Benny, MD	2

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
072	Pecora, Andrew L., MD	The Cancer Center at Hackensack University Medical Center 30 Prospect Avenue Hackensack, NJ 07601 United States of America	Alter, Robert S., MD Jennis, Andrew A., MD Harper, Harry D., MD Pascal, Mark S., MD Rosenbluth, Richard J., MD Waintraub, Stanley E., MD	5
073	Scola, Michael, MD	Hematology-Oncology Associates of Northern New Jersey Carol G. Simon Cancer Center 100 Madison Avenue Morristown, NJ 07962 United States of America	Adler, Kenneth, MD Bayer-Gore, Constance, RN DeRosa, William, DO Early, Ellen, MD Farber, Charles, MD Gerstein, Gary, MD Leibowitz, Stacey, MD Papish, Steven, MD	1
074	Wax, Michael, MD	Summit Medical Group 1 Diamond Hill Road Bensley Pavilion, Oncology Dept Berkeley Heights, NJ 07922 United States of America	Scheff, Ronald, MD Wildman, Joseph, MD	1
075	Goydos, James, MD Stein, Mark, MD Germino, Joseph, MD	The Cancer Center Institute of New Jersey 195 Little Albany Street New Brunswick, NJ 08901 United States of America	Stein, Mark, MD Germino, Joseph, MD Goydos, James, MD Mehnert, Janice, MD	2

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
~~121~~	~~Schuchter, Lynn, MD~~	~~University of Pennsylvania Abramson Cancer Center 3400 Spruce Street, Penn Tower Bldg Philadelphia, PA 19104 United States of America~~	~~Flaherty, Keith, MD~~	~~0~~
122	Drabick, Joseph, MD	Penn State Milton S. Hershey Hershey Medical Center Penn State Cancer Institute/H056 500 University Drive Hershey, PA 17033-0850 United States of America	DuBrock, Cynthia, RN Harvey, Harold, MD Kimble, Rose, MD Lander, Mary, RN, OCN Lipton, Allan, MD Miller, Rebecca, RN Ottaviano, John, RN BSN	1
123	Kirkwood, John M., MD	University of Pittsburgh Division of Oncology Hillman Cancer Research Pavilion 5117 Centre Avenue, 1.32 Pittsburgh, PA 15213 United States of America	Agarwala, Sanjiv S., MD Brown, Charles K., MD Coulson, Rayanne, PA-C DeMark, Melissa, PA-C Edington, Howard David James, MD Moschos, Stergios, MD Shipe-Spotloe, Janice M., PA-C Tarhini, Ahmad, MD Tawbi, Hussein, MD Zarour, Hassane, MD	5

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
130	Haas, Naomi, MD	Fox Chase Cancer Center 333 Cottman Avenue Philadelphia, PA 19111 United States of America	Paul, Jennifer, PA-C von Mehren, Matgaret, MD Millenson, Michael, MD	1
145	Mastrangelo, Michael, MD	Thomas Jefferson University 125 South 9th Street Suite 801 Philadelphia, PA 19107 United States of America	Feeney, Kendra, MD Sato, Takami, MD	1
162	Collichio, Frances A., MD	Hematology/Oncology University of North Carolina at Chapel Hill 3009 Old Clinic Building, CB# 7305 Chapel Hill, NC 27599-7050 United States of America	Ollila, David, MD Carrizosa, Daniel R., MD	1
163	Amin, Asim, MD White, Richard, MD	Blumenthal Cancer Center 1000 Blythe Boulevard Charlotte, NC 28203 United States of America	Amin, Asim, MD Brick, Wendy, MD Frenette, Gary, MD Hogan, Denise, RN Packman, Charles, MD Salo, Jonathan, MD White, Richard, MD	1

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
166	Hodi, Frank Stephen, MD	Dana Farber Cancer Institute 44 Binney Street, Dana 540C Boston, MA 02115 United States of America	Atkins, Michael, MD Bhatt, Rupal, MD Canning, Christine, PA-C Cho, Daniel, MD Farquhar, Mary, RN Friedlander, Philip, MD Haluska, Frank, MD Hsu, Arlene, RN Koon, Henry, MD Lawrence, Donald, MD McDermott, David, MD Mier, James, MD Mac Rae, Suzanne, RN Nelson, Mary Beth, RPA-C Rubin, Krista, RN Rattner, Barbara, RN Seery, Virginia, NP Smith, David, MD Tsiaras, Argyro	15

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
167	Hodi, Frank Stephen, MD	Beth Israel Dec Medical Center 330 Brookline Avenue Boston, MA 02115 United States of America	Atkins, Michael, MD Bhatt, Rupal, MD Canning, Christine, PA-C Cho, Daniel, MD Farquhar, Mary, RN Friedlander, Philip, MD Haluska, Frank, MD Hsu, Arlene, RN Koon, Henry, MD Lawrence, Donald, MD McDermott, David, MD Mier, James, MD Mac Rae, Suzanne, RN Nelson, Mary Beth, RPA-C Rubin, Krista, RN Rattner, Barbara, RN Seery, Virginia, NP Smith, David, MD Tsiaras, Argyro	28

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
168	Hodi, Frank Stephen, MD	Massachusetts General Hospital 55 Fruit Street Boston, MA 02114 United States of America	Atkins, Michael, MD Bhatt, Rupal, MD Canning, Christine, PA-C Cho, Daniel, MD Farquhar, Mary, RN Friedlander, Philip, MD Haluska, Frank, MD Hsu, Arlene, RN Koon, Henry, MD Lawrence, Donald, MD McDermott, David, MD Mier, James, MD Mac Rae, Suzanne, RN Nelson, Mary Beth, RPA-C Rubin, Krista, RN Rattner, Barbara, RN Seery, Virginia, NP Smith, David, MD Tsiaras, Argyro	4
171	Kluger, Harriet, MD	Yale University School of Medicine 333 Cedar St New Haven, CT 06520 United States of America	Sznol, Mario, MD	2

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
176	Sharfman, William H., MD	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 10753 Falls Road, Suite 415 Lutherville, MD 21093 United States of America	Burks, Kathleen L., RN Fecher, Leslie, MD Kedhar, Sanjay, MD Kempen, John, MD Radebaugh, Lisa, RN Santmyer, JoAnn, RN	3
177	Zapas, John Louis, MD	The Harry and Jeanette Weinberg Cancer Institute Franklin Square Hospital 9103 Franklin Square Drive, Suite 2300 Baltimore, MD 21237 United States of America	McCarron, Edward, MD Waterfield, William, MD	3

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
~~181~~	~~Conkling, Paul, MD~~	Virginia Oncology Associates 5900 Lake Wright Drive Norfolk, VA 23502 United States of America	Alberico, Thomas A., MD Alexander, Burton F. III, MD Atienza, Daniel M., MD Burger, Robert L., MD Casper, Robbie, RN Cross, Scott J., MD Depanfilis, Cara, PA-C Dorson, Loretta, NP-C Foster, Andrea, PA Friedman, Elke K., MD George, Edward R., MD Howard, John Randolph, MD King, Marilyn Parker, RN Lee, Michael Edward, MD McGaughey, Dean S., MD Poulin, Eric, PA-C Saman, S. George, MD Sawyer, Linda, NP-C Scotese, Cecelia, PA-C Steinberg, Michael S., MD Thompson, Angela, PA Thurman-Walker, Audrey, NP-C	~~0~~

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
186	Stephenson, Joe J., Jr., MD	Cancer Center of the Carolinas 65 International Drive Greenville, SC 29615 United States of America	Bowers, Charles, MD Brooker, Reginald J., MD Christman, Kathy L., MD Edenfield, William J., MD Ferguson, Catherine L., MD Giguere, Jeffrey K., MD Gluck, W. Larry, MD Gococo, Kim O., MD Hunter, John D., MD O'Rourke, Mark A., MD Spitzer, Gary, MD Walls, Jay D., MD Wilcox, Jeannette L., MD Wood, Samuel, MD Yee, Kim Hont A., MD Zurenko, Michael D., MD	6
197	Lawson, David, MD	Emory University 1365 Clifton Road NE Atlanta, GA 30322 United States of America	Kim, Joung, MD Maynard, Necia, NP	8
206	Chesney, Jason, MD McMasters, Kelly M., MD, PhD	University of Louisville Brown Cancer Center 529 South Jackson Street Louisville, KY 40202 United States of America	Laber, Damian, MD Miller, Donald, MD	1

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
~~207~~	~~Tate, Peter, MD~~	~~Central Baptist Hospital 1760 Nicholasville Road Suite 202 Lexington, KY 40503 United States of America~~	~~Eldridge, Russell, MD Hicks, Lee, MD~~	~~0~~
211	Borden, Ernest, MD	The Cleveland Clinic Foundation 9500 Euclid Avenue, R40 Cleveland, OH 44195 United States of America	Bray, Julie, NP-C Budd, George Thomas, MD Bukowski, Ronald, MD Kim, Julian, MD Lipnickey, Victoria, PA-C Spiro, Timothy, MD Triozi, Pierre, MD	8

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
~~212~~	~~Vrindavanam, Nanda, MD~~	~~Signal Point Hematology/Oncology, Inc. 235 North Breiel Boulevard Middletown, OH 45042 United States of America~~	~~Bane, Charles, MD Calvo, Alejandro, MD Collins, Mark, MD Gordon, Gregory, MD Gross, Howard, MD Haluschak, John, MD Jilani, Shamim, MD Kathula, Satheesh, MD Koduri, Jhansi, MD Lanville, Joseph, MD Malcolm, Albert, MD Merl, Stuart, MD Raju, Robert, MD Romer, Mark, MD Sabagh, Tarek, MD Sabiers, James, MD Shah, Ketan, MD Skinner, Cheryl, MD Yanes, Burhan, MD~~	~~0~~
216	Leming, Philip D., MD	The Christ Hospital Cancer Center Research 2139 Auburn Avenue, D Level Cincinnati, OH 45219 United States of America	Cody, Robert, MD Elluru, Heather, PA-C Leder, Wilfried, MD Mannion, Brian, MD Patil, Sadanand, MD Stanisic, Slobodan, MD Weichert, Kathryn, MD	3

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
221	Chapman, Robert, MD	Henry Ford Health System 2799 West Grand Boulevard Detroit, MI 48202 United States of America	Anderson, Joseph, MD Ali, Haythem, MD Barthel, Bernd, MD Bola, Paradeep, R.Ph., MS Bricker, Leslie, MD Cotanat, Matthew, MD Dabak, Vrushali, MD Doyle, Thomas, MD Gaykazyan, Susanna, MD Hanbali, Amr, MD Janakiraman, Nalini, MD Kamboj, Ginny, MD Kaseb, Ahmed, MD Kuriakose, Philip, MD Loutfi, Randa, MD Sohal, Gurjyot, MD Stoltenberg, Michael, MD Tejwani, Sheela, MD Vega, Jose, MD Wang, Ding, MD Wollner, Ira, MD Yates, Todd, MD Zuberi, Lara, MD	4

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
226	Khan, Khuda Dad, MD	American Health Network of IN, LLC 8111 South Emerson Avenue Suite A, Indianapolis, Indiana 46237 United States of America	Ali Al-Nsour, Mohommad, MD Anderson, Jeanette, PA-C Bates, Laurence, MD Cooper, Maureen, MD Slaughter, Michael T., MD Smith, Gregory W., MD Trowbridge, Randall C., MD Turner, Tamika, NP-C	6
227	Schwartzentruber, Douglas, MD	Center for Cancer Care at Goshen Health System 200 High Park Avenue Goshen, IN 46526 United States of America	Bruetman, Daniel, MD Cohen, Joel, MD Gonyon, Deana, NP Gulec, Seza, MD Hostetter, Richard, MD Pennington, Kenneth, MD Rheinheimer, Kristan, NP	1
231	Wade, James, MD	Cancer Care Specialists of Central Illinois 2880 North Monroe Street Decatur, IL 62526 United States of America	Dy, Philip, MD Esparaz, Benjamin, MD Estrada-Garcia, Dolores, MD Guaglianone, Perry, MD Floyd, Justin, DO Matthews, Frances, MD Perdekamp, Maria Theresia Gross, MD Velasco Jr, Mario , MD	1

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
233	Clark, Joseph I., MD	Loyola University Medical Center Cardinal Bernardin Cancer Center 2160 S. 1st Avenue Maywood, IL 60153 United States of America	Gil, Amaryllis, MD Lo, Shelly, MD Smith, Scott, MD	10
~~234~~	~~Conlon, Kevin, MD~~	~~Rush University Medical Center 1725 West Harrison Street, Suite 821 Chicago, IL 60612 United States of America~~	~~Bonomi, Philip, MD Leslie, William, MD~~	~~0~~
236	Anderson, Clay, MD	Ellis Fischel Cancer Center University of Missouri Health Care 115 Business Loop 70 West Columbia, MO 65203 United States of America	Doll, Donald, MD Freter, Carl, MD Papageorgio, Chris, MD Perry, Michael C, MD Shahabuddin, Nasir, MD	4
237	Linette, Gerald, MD	Washington University School of Medicine 660 S. Euclid Avenue Campus Box 8007 St. Louis, MO 63110 United States of America	Adkins, Douglas Ray, MD Cornelius, Lynn, MD Ellis, Matthew M.B., PhD., FRCP Naughton, Michael, MD Pluard, Timothy, MD Weilbaecher, Katherine, MD	11
238	Rangineni, Raj, MD	St. Joseph Oncology, Inc. 902 North Riverside Road, Suite 200 St. Joseph, MO 64507 United States of America	Chatfield, Charles, FNP Gupta, Vicram, MD Jawde, Rony, MD McDaniel, Dana, NP Weigand, Robert, MD	2

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
241	Figueroa, Jose A., MD	Joe Arrington Cancer Research and Treatment Center 4101 22nd Place Lubbock, TX 79410 United States of America	Close, David R., MD Cruz, Jose Carlos, MD Cummings, David A., MD Di Nunno, Lucio, MD Quick, Donald P., MD Shalaby, Ibrahim A., MD Tafur, Isaac, MD	4
242	Khurshid, Anwar, MD	Arlington Cancer Center 906 West Randol Mill Road Arlington, TX 76012 United States of America	Adams, John, DO Akbani, Sohail, MD Blumenschein, George, MD Dicke, Karel, MD DiStefano, Alfred, MD Firstenberg, Barry, DO	2
244	Mirtsching, Barry, MD	Center for Oncology Research and Treatment 7777 Forest Lane, Suite B242 Dallas, TX 75230 United States of America	Ortiz, Vanessa, MD	3
261	Gonzalez, Rene, MD	University of Colorado Health Sciences Center 1665 North Ursula Street, Room 3240 Aurora, CO 80010 United States of America	Chawla, Ashish Grimm, Alexander Kudchadkar, Ragini, MD Lewis, Karl, MD Robinson, William, MD Russ, Paul, MD	15

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
262	Fleagle, John, MD	Rocky Mountain Cancer Centers 4715 Arapahoe Avenue Boulder, CO 80303 United States of America	Albert, Katherine, NP Anderson, Paul, MD Berris, Robert, MD Burke, John, MD Busby, Leslie, MD Cohn, Allen, MD DeCarolus, Paul, MD Diab, Sami, MD DiBella, Nicholas, MD Faragher, David, MD Feiner, Alan, MD Fox, Jenny, MD Frank, Stephen, MD Freeman, Susan, MD Gates, Rose, NP Hinshaw, Ioana, MD Johnson, Michael, MD Jotte, Robert, MD Kovachy, Robin, MD Link, David, MD Logsdon, Matthew, MD Mack, Kelly, NP	2

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
262	Fleagle, John, MD	Rocky Mountain Cancer Centers 4715 Arapahoe Avenue Boulder, CO 80303 United States of America	Matei, Carmen, MD McCroskey, Dana, PA McMahon, Richard, MD Moran, Patrick, MD Otsuka, Alvin, MD Reznick, Douglas, MD Rifkin, Robert, MD Sayre, Robert, MD Schlatter, Monica, NP Sitarik, Mark, MD Soriano, Ariel, MD Tolley, Russell, MD Zinn Jr., Charles, MD	

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
264	Fleagle, John, MD	Rocky Mountain Cancer Center 34 Van Gordon Street Suite 160 Lakewood, CO 80228 United States of America	Albert, Katherine, NP Anderson, Paul, MD Berris, Robert, MD Burke, John, MD Busby, Leslie, MD Cohn, Allen, MD DeCarolus, Paul, MD Diab, Sami, MD DiBella, Nicholas, MD Faragher, David, MD Feiner, Alan, MD Fox, Jenny, MD Frank, Stephen, MD Freeman, Susan, MD Gates, Rose, NP Hinshaw, Ioana, MD Johnson, Michael, MD Jotte, Robert, MD Kovachy, Robin, MD Link, David, MD Logsdon, Matthew, MD Mack, Kelly, NP Matei, Carmen, MD McCroskey, Dana, PA McMahon, Richard, MD Moran, Patrick, MD Otsuka, Alvin, MD	2

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
264	Fleagle, John, MD		Reznick, Douglas, MD Rifkin, Robert, MD Sayre, Robert, MD Schlatter, Monica, NP Sitarik, Mark, MD Soriano, Ariel, MD Tolley, Russell, MD Zinn Jr., Charles, MD	
~~266~~	~~Burke, John, MD~~	Rocky Mountain Cancer Centers 3027 North Circle Drive Colorado Springs, CO 80909 United States of America	Anderson, Paul, MD DeCarolis, Paul, MD Gates, Rose, NP ~~Logsdon, Matthew, MD~~ Matei, M. Carmen, MD Sayre, Robert, MD Zinn, Jr., Charles, MD	~~0~~

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
267	Cohn, Allen, MD	Rocky Mountain Cancer Centers 1800 Williams Street, Suite 200 Denver, CO 80218 United States of America	Albert, Katherine, NP Berris, Robert, MD Diab, Sami, MD DiBella, Nicholas, MD Faragher, David, MD Feiner, Alan, MD Freeman, Susan, MD Hinshaw, Ioana, MD Jotte, Robert, MD Kovachy, Robin, MD Link, David, MD Mack, Kelly, NP McCroskey, Dana, PA McMahon, Richard, MD Reznick, Douglas, MD Rifkin, Robert, MD Soriano, Ariel, MD	1

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
268	Cohn, Allen, MD	Rocky Mountain Cancer Center 1700 South Potomac Street Aurora, CO 80012 United States of America	Albert, Katherine, NP Berris, Robert, MD Diab, Sami, MD DiBella, Nicholas, MD Faragher, David, MD Feiner, Alan, MD Freeman, Susan, MD Hinshaw, Ioana, MD Jotte, Robert, MD Kovachy, Robin, MD Link, David, MD Mack, Kelly, NP McCroskey, Dana, PA McMahon, Richard, MD Reznick, Douglas, MD Rifkin, Robert, MD Soriano, Ariel, MD	1

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
~~270~~	~~Cohn, Allen, MD~~	Rocky Mountain Cancer Center 22 West Dry Creek Circle Littleton, CO 80120 United States of America	Albert, Katherine, NP Berris, Robert, MD Diab, Sami, MD DiBella, Nicholas, MD Faragher, David, MD Feiner, Alan, MD Freeman, Susan, MD Hinshaw, Ioana, MD ~~Jotte, Robert, MD~~ Kovachy, Robin, MD Link, David, MD Mack, Kelly, NP McCroskey, Dana, PA McMahon, Richard, MD Reznick, Douglas, MD Rifkin, Robert, MD Soriano, Ariel, MD	~~0~~

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
~~271~~	~~Cohn, Allen, MD~~	~~Rocky Mountain Cancer Center 10103 Ridge Gate Parkway Suite G-01 Lone Tree, CO 80124 United States of America~~	~~Albert, Katherine, NP Berris, Robert, MD Diab, Sami, MD DiBella, Nicholas, MD Faragher, David, MD Feiner, Alan, MD Freeman, Susan, MD Hinshaw, Ioana, MD Jotte, Robert, MD Kovachy, Robin, MD Link, David, MD Mack, Kelly, NP McCroskey, Dana, PA McMahon, Richard, MD Reznick, Douglas, MD Rifkin, Robert, MD Soriano, Ariel, MD~~	~~0~~
281	Ward, John Harris, MD Samlowski, Wolfram, MD	Huntsman Cancer Institute 2000 Circle of Hope, Suite 5245 Salt Lake City, UT 84112-5550 United States of America	Akerley, Wallace, MD Morrison, Lynn, NP Smit, Julie, NP Ward, John Harris, MD	13

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
~~285~~	~~Liebmann, James E., MD~~	~~New Mexico Oncology Hematology Consultants, Ltd. 4901 Lang Avenue, NE Albuquerque, NM 87109 United States of America~~	~~Alidina, Aryn G., MD Clark, Douglas A., MD Costello, Daniel G., PA Fontaine, Annette C., MD Giudice, Richard O., MD Haskins, Clark, MD~~ Hercasitas, Darling J., PA Malik, Imtiaz, MD Marshall, Natalie A., MD McAneny, Barbara L., MD Merin, Jan M., MD Smoker, Mikal A., PA	~~0~~

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
286	Hersh, Evan, MD	Arizona Cancer Center 1515 North Campbell Avenue Tucson, AZ 85724-5024 United States of America	Ahn, Sang-Hoon, MD Antic, Nenad, MD Choi, James, MD Cranmer, Lee, MD Davis, Rohonda, RN Downey, Leona, MD Elquza, Emad, MD Glennie, Anna, RN Gerstner, Gregory, MD Horton, Carolyn, RN Jeter, Joanne, MD Jones, Carolyn, RN, ACNP Klinkhammer, Thomas, MD Kurtin, Sandra, RN Miller, Margaret, MD Nichols, Heather, RN Poulin, Veronique, MD Sharifi, Agnes, FNP-C Swaney III, Robert, MD Swart, Rachel, MD, PhD Taylor, Sandra, MD	8

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
291	Urba, Walter, MD	Providence Portland Medical Center 4805 NE Glisan, 5F40 Portland, OR 97213 United States of America	Bernstein, Eric, MD Crocenzi, Todd, MD Curti, Brendan, MD Lufkin, Robert, DO Nichols, Craig, MD Ross, Helen, MD Smith II, John, MD	5
301	Sosman, Jeffrey A., MD	Division of Hematology/Oncology Vanderbilt University Medical Center 777 Preston Research Building Nashville, TN 37232-6307 United States of America	Goff, Laura, MD Hande, Ken, MD Kelley, Mark, MD Lockhart, Craig, MD Puzanov, Igor, MD Roth, Bruce, MD Wyman, Ken, MD	19

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
302	Blakely, Laura, MD	The West Clinic 100 North Humphreys Boulevard Memphis, TN 38120 United States of America	Arnold, Anita, MD Bailey, Nancy, MSN Baum, Scott L., MD Beard, Tammara, FNP Benn, Sonia, MD Besh, Stephen, MD Bosche, Saundra, APRN Heching, Norman, MD Hodgkiss, Thomas D., MD Hoffmann, Emily, FNP Howe, Kathryn Hudson, Angela, FNP Humble, Carol, ANP Johnson, Robert, MD Kanter, Lisa, APRN Lankford, William A., MD Lawson, Ronald, MD Marcum, Carolyn, APRN Mars, Christy, APRN O'Connor, Maurine, MD Norris, Marcus, MD Paller, Arnel, MD Pratt, Thomas, MD Reed, Jarvis, MD Richey, Sylvia, MD Schwartzberg, Lee, MD Somer, Bradley, MD	5

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
302	Blakely, Laura, MD		Strong, C'Sara Rae, APRN Tauer, Kurt, MD Tian, G.Gary, MD Wheeler, Benton, MD	
303	Weeks, Albert, MD	Family Cancer Center, PLLC 1936 Poplar Avenue West Collierville, TN 38017 United States of America	Gore, Margaret, MD Gravenor, Donald, MD Obaji, Suhail, MD Sullivan, David, MD Tian, Gary, MD Walsh, William, MD	1

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
316	Amatruda, Thomas, MD	Hubert H. Humphrey Cancer Center 3435 West Broadway Suite 1135 Robbinsdale, MN 55422 United States of America	Anderson, Jade, MD Benson, Terry, RN Bloom, Stuart, MD Cardamone, Jr., Joseph, MD Erickson, Carmen, CNP Garino, Lucia, MD Kern, Jacqueline, R.Ph. King, David, MD Larson, Tim, MD Laudi, Noel, MD Lew, Erin, NP Londer, Harold, MD Mann, Stephen, MD Nagargoje, Gauri, MD Oken, Martin, MD Pawloski, Pamala, PharmD Penning, Heather, NP Pennington, Karen, PA-C Siemers, Ross, MD Sjoquist, Nina, NP Stella, Amy, MD Sundeen, Nancy, RN Thomas, Rebecca, MD Uhlman, Dorothy, MD Winston, Robert, MD	6

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
336	Burdette-Radoux, Susan, MD	Fletcher Allen Health Care 89 Beaumont Avenue, Given E214 Burlington, VT 05405 United States of America	Grant, Barbara , MD Greenblatt, Marc, MD Grunberg, Steven, MD Larson, Paul, NP Muss, Hyman, MD Olin, Julie, MD Ornstein, Deborah, MD Philips, George, MD Wood, Marie, MD	2
350	Cheng, Tina, MD	Tom Baker Cancer Centre 1331 29th Street, NW Calgary, Alberta T2N 4N2 Canada	Eigl, Bernhard, MD	1
~~351~~	~~Smylie, Michael, MD~~	~~Cross Cancer Institute 11560 University Avenue Edmonton, Alberta T6Q 1Z2 Canada~~	~~Joy, Anil Abraham, MD~~	~~0~~
~~352~~	~~Younus, Jawaid, MD Lohmann, RC, MD~~	~~London Regional Cancer Center 790 Commissioners Rd. E. London, Ontario, N6A 4L6 Canada~~	~~Younus, Jawaid, MD~~	~~0~~
~~354~~	~~Thomas, Luc, MD~~	~~Hopital de l'Hotel Dieu Service de Dermatologie 1, Place de l'Hopital 69296 Lyon Cedex 02 France~~	~~Dalle, Stephane, MD~~	~~0~~

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
355	Baetz, Tara, MD	Cancer Centre of Southeastern Ontario at KGH 25 King Street West Kingston, Ontario, K7L 5P9 Canada	Eisenhower, Elizabeth, MD El-Dafrawy, Sherif, MD	3
356	Miller, Wilson, MD	Sir Mortimer B. Davis - Jewish General Hospital 3755 Chemin de la Cote-Ste-Catherine Montreal, Quebec H3T 1E2 Canada	Batist, Gerald, MD Kavan, Petr, MD Langleben, Adrian, MD Melynychuk, David, MD Patenaud, Grancois, MD	5
357	Hogg, David, MD Ian Quirt, MD	Princess Margaret Hospital 610 University Avenue 5-209 Toronto, Ontario M5G 2M9 Canada	Baker, Michael, MD Hogg, David, MD Joshua, Anthony, MD	10
359	Rorke, Stewart, MD	Dr. H. Bliss Murphy Cancer Centre 300 Prince Philip Drive St. John's, NL A1B 3V6 Canada	Ahmad, Chaudhary, MD Laing, Kara, MD McCarthy, Joy, MD Siddique, Jehan, MD Zaidi, Adnan, MD Zulfiqar, Muhammad, MD	1
360	Verma, Shailendra, MD	The Ottawa Hospital Regional Cancer Centre 501 Smyth Road Ottawa, Ontario K1H 8L6 Canada	Keller, Oliver, MD Young, Vincent, MD	6
361	Wong, Ralph, MD	CancerCare Manitoba St. Boniface Unit 409 Tache Avenue Winnipeg, MB R2H 2A6 Canada	Latosinsky, Steven, MD Nason, Richard, MD Saettler, Elizabeth, MD Wiseman, Marni, MD	1

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
370	Gore, Martin E., Prof./MD	Royal Marsden Hospital Department of Medicine 203 Fulham Road London SW3 6JJ United Kingdom	Ahmed, Mahbabl, MD Ang, Joo Ern, MD Baird, Richard, MD Banerji, Udai, MD Benepal, Tahir, MD Benson, Charlotte, MD Blagden, Sarah Patricia, MD Constantinidou, Anastasia, MD Carden, Craig, MD Denman, Elizabeth, MD Eisen, Timothy George Quentin, MD Ferguson, Thomas, MD Fuser, Bruno, MD Gerlinger, Marco, MD Harrison, Michelle, MD Hewish, Madeline, MD James, Margaret, MD Josephs, Debra, MD Karavasilis, Vasilios, MD Kipps, Emma, MD Kriszteleit, Rebecca, MD Larkin, James, MD Linch, Mark, MD Miller, Rowan, MD Molife, Rhoda, MD Montes, Ana, MD	6

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
370	Gore, Martin E., Prof./MD	Royal Marsden Hospital Department of Medicine 203 Fulham Road London SW3 6JJ United Kingdom	Nicum, Shibani, MD Noble, Jillian, MD Nowicki, Stefan, MD Okines, Alicia, MD Parton, Marina, MD Papadopoulos, Panagiotis, MD Pickering, Lisa Peeke, Laura, MD Pyle, Lynda, MD Dr. Ramsey Ratnayake, Gihan, MD Reade, Sarah, MD Roux, Rene, MD Sandhu, Shahneen Sarker, Debashis, MD Sinah, Rajesh, MD Sirohi, Bhawna, MD Stanway, Susannah, MD Swanton, Charles, MD Van Hagen, Thomas, MD	

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
371	Houston, Stephen, MD	St Luke's Cancer Centre The Royal Surrey County Hospital Egerton Road Guildford Surrey, GU2 7XX United Kingdom	Baird, Richard, MD Dolly, Saoirse, MD Miller, Rowan, MD Stanway, Susie, MD	3
372	Kelly, Charles G., MD	Northern Centre for Cancer Treatment Newcastle General Hospital Westgate Road Newcastle-upon-Tyne NE4 6BE United Kingdom	Loo, Vivian, MD Plummer, Ruth, MD Razak, Albiruni, MD	1
373	Hancock, Barry, Prof. Danson, Sarah, MD	University of Sheffield Cancer Research Centre Weston Park Hospital Whitham Road Sheffield S10 2SJ United Kingdom	Brown, Janet, MD Cunnell, Michelle, MD Lester, James, MD Martin, Jacqueline, MD Shankland, Kate, MD Young, Robin, MD	2

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
375	Ottensmeier, Christian H., MD	Somers Cancer Research Building MP 824 Southampton General Hospital Tremona Road Southampton Hampshire SO16 6YD United Kingdom	Boleti, Ekaterini Gorf, Lauren Gray, J, MD Hall, V, MD Kerr, J.P., MD Nolan, Luke, MD Owadally, Waheeda	10
376	Patel, Poulam M., MD	Nottingham University Hospitals NHS Trust City Campus Academic Unit of Clinical Oncology Hucknall Road, Nottingham NG5 1PB United Kingdom	Chaudhuri, Anupan, MD Conn, Andrew J, MD Gossage, Lucy, MD Khan, Sarah, MD Ullenhag, Gustav, MD Wood, Joanna, MD	4
~~377~~	~~Selby, John, Prof./MD~~	~~Cancer Research UK Clinical Centre St. James University Hospital Beckett Street Leeds LS9 7TF United Kingdom~~	~~Beirne, Deborah, MD Cardale, Joanna Katherine, MD Hanzlik, Renata, MD Marples, Maria, MD Sugden, Johanne, MD Yeoh, Cheng, MD~~	~~0~~

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
378	Barber, Jim, MD	Velindre Cancer Centre Velindre NHS Trust Velindre Road Whitchurch Cardiff CF14 2TL United Kingdom	Abbas, T, MD Davies, Rachel, MD Gwynne, Sarah, MD Micallef, Rachel, MD Parker, Katherine, MD	6
381	Lorigan, Paul, MD	University of Manchester Dept of Medical Oncology Christie Hospital NHS Trust Wilmslow Road, Withington M20 4BX United Kingdom	Amir, Ethan, MD Board, Ruth, MD Califano, Rafaele Carter, Louise, MD Chow, Shien, MD Clamp, Andrew, MD Dangoor, Adam, MD Danson, Sarah, MD Gibb, Adam, MD Griffiths, Richard, MD Harle, Emily, MD Hughes, Sarah Anne, MD Jyoti, Babita, MD Karina, Maria, MD Khoja, Leila, MD Laking, George, MD Lao, Sin, MD Peck, Rahul, MD Ton, Chan, MD Thistlethwaite, Fiona, MD	12

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
~~382~~	~~Osborne, Richard, MD~~	~~Dorset Cancer Centre Poole Hospital NHS Trust Longfleet Road Poole Dorset BH15 2JB United Kingdom~~	~~None~~	~~0~~
383	Rankin, Elaine, Prof./MD	Department of Cancer Medicine Ninewells Hospital & Medical School Dundee DD1 9SY Scotland United Kingdom	Ali, Clinton, MD Forbes, Deborah, RN Goodman, Fiona, RN Guild, Audrey, RN Verborg, Wouter, MD	1
384	Middleton, Mark, MD	University of Oxford, Cancer Research United Kingdom, Medical Oncology Unit Churchill Hospital Old Road Headington Oxford OX3 7LJ United Kingdom	Azam, Faisal, MD Karydis, Ioannis, MD Khan, Omar, MD Madhusudan, Srinivasan, MD Moosa, Yaaseen, Prof/MD Sabharwal, Ami, MD Samol, Jens, MD	7

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
385	Gore, Martin E., Prof./MD	Royal Marsden Hospital Downs Road Sutton Surrey SM2 5PT United Kingdom	Ahmed, Mahbabl, MD Ang, Joo Ern, MD Baird, Richard, MD Banerji, Udai, MD Benepal, Tahir, MD Benson, Charlotte, MD Blagden, Sarah Patricia, MD Constantinidou, Anastasia, MD Carden, Craig, MD Denman, Elizabeth, MD Eisen, Timothy George Quentin, MD Ferguson, Thomas, MD Fuser, Bruno, MD Gerlinger, Marco, MD Harrison, Michelle, MD Hewish, Madeline, MD James, Margaret, MD Josephs, Debra, MD Karavasilis, Vasilios, MD Kipps, Emma, MD Kriszteleit, Rebecca, MD Larkin, James, MD Linch, Mark, MD Miller, Rowan, MD Molife, Rhoda, MD Montes, Ana, MD	3

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
385	Gore, Martin E., Prof./MD	Royal Marsden Hospital Downs Road Sutton Surrey SM2 5PT United Kingdom	Nicum, Shibani, MD Noble, Jillian, MD Nowicki, Stefan, MD Okines, Alicia, MD Parton, Marina, MD Papadopoulos, Panagiotis, MD Pickering, Lisa Peeke, Laura, MD Pyle, Lynda, MD Dr. Ramsey Ratnayake, Gihan, MD Reade, Sarah, MD Roux, Rene, MD Sandhu, Shahneen Sarker, Debashis, MD Sinah, Rajesh, MD Sirohi, Bhawna, MD Stanway, Susannah, MD Swanton, Charles, MD Van Hagen, Thomas, MD	
391	Lesimple, Thierry, MD	Centre Eugène Marquis Service d'Oncologie Médicale Avenue de la Bataille Flandres Dunkerque CS 44229 35042 RENNES Cedex, France	Botton, Estelle, MD Lefeuve-Plesse, Claudia, MD Vauleon, Elodie, MD	5

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
392	Negrier, Sylvie, MD	Centre Léon Bérard Département de Cancérologie Médicale 28, rue Laënnec 69373 LYON Cedex 08, France	De La Fourchadiere, Christelle, MD Neidhart-Berard, Eve-Marie, MD Zufferey-Brousseau, Laura, MD	3
393	Dreno, Brigitte, Prof./MD	CHU de Nantes - Hôtel Dieu UF Cancéro-Dermatologie 1 Place Alexis Ricordeau 44093 NANTES Cedex 1, France	Brocard, Anabelle, MD Ballanger, Fabienne, MD Wallon-Dumont, Gwenaëlle, MD Quereux, Gaëlle, MD	9
395	Robert, Caroline, MD	Institut Gustave Roussy Service d'Immunothérapie 39, rue Camille Desmoulins 94800 VILLEJUIF Cedex, France	Arnault, Jean-Philippe, MD Autier, Julien, MD Escudier, Bernard, MD Ghiringhelli, Francois, MD Mateus, Christine, MD	15
~~396~~	~~Boulinquez, Serge, MD~~	~~Hopital La Grave Service de Dermatologie et de Medecine Sociale Place Lange TSA 60033 31059 Toulouse Cedex 09, France~~	~~Viraben, Roland, MD~~	~~0~~
397	Geoffrois, Lionel, MD	Centre Alexis Vautrin Département d'Oncologie Médicale Avenue de Bourgogne 54500 VANDOEUVRE-LES-NANCY France	Uwer, Lionnel, MD Dietemann, Anne, MD	8

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
398	Dereure, Oliver, MD	Hôpital Saint-Eloi Service de Dermatologie 80, avenue Augustin Fliche 34295 MONTPELLIER Cedex 5 France	Guillot, Bernard, Prof./MD	1
~~399~~	~~Misery, Laurent, Prof./MD~~	~~Hôpital Morvan Service de Dermatologie 5, avenue Foch 29609 BREST Cedex France~~	~~Roguedas, Anne-Marie, MD Sassolas, Bruno, MD~~	~~0~~
400	Penel, Nicholas, MD	Centre Oscar Lambret Département de Cancérologie Générale 3, rue Frédéric Combemale 59020 LILLE France	Dansin, Eric, MD Degardin, Marian, MD Hoguet, Dominique, MD	1
401	Grob, Jean-Jacques, Prof./MD	Hôpital Sainte-Marguerite AP-HM Hôpitaux Sud Service de Dermatologie - Vénéréologie 270 boulevard Sainte Marguerite 13009 MARSEILLE France	Gashon-Bufferet, Julie, MD Gaudy- Marqueste, Caroline, MD Monestier, Sandrine, MD Nicol, Isabelle, MD Richard-Lallemant, Marie-Aleth, Prof./MD	6
~~402~~	~~Joly, Pascal, Prof./MD~~	~~CHU de Rouen - Hôpital Charles Nicolle Clinique Dermatologique - Porte 12 Anciens Bâtiments - 1, rue de Germont 76031 ROUEN Cedex, France~~	~~Cordel, Nadege, MD De Quatrebarbes, Julie, MD Duval-Modeste, Anne-Bénédicte, MD~~	~~0~~

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
403	Lebbe, Celeste, Prof./MD	Hôpital Saint Louis Service de Dermatologie 1 avenue Claude Vellefaux 75475 PARIS Cedex 10, France	Bruzzoni-Giovanelli, Herberto, MD Calvo, Fabien, Prof./MD De Gouvello, Amaury, MD Kerob, Delphine, MD Levy, Vincent, MD Regnier, Stephanie, MD Schartz, Noël, MD	10
~~404~~	~~Delaunay, Michele, MD~~	Hopital Saint Andre Unite de Dermatologie Cancerologique ~~1, rue Jean Burguet~~ 33075 Bordeaux Cedex France	Ravaud, Alain, MD ~~Jouary, Thomas, MD~~ Dilhuydy, Marie-Sarah, MD	~~0~~
405	Cambazard, Frederic, Prof./MD	CHU de Saint Etienne Hospital Nord Service de Dermatologie 42055 SAINT-ETIENNE Cedex 2, France	Brunacci, Nadege, MD Denis-Thely, Laurence, MD LaBeille, Bruno, MD Perrot, Jean-Luc, MD	4
~~406~~	~~Souteyrand, Pierre, Prof./MD~~	CHU de Clermont-Ferrand Hôtel Dieu Service de Dermatologie Boulevard Léon Malfreyt 63058 CLERMONT-FERRAND Cedex France	Amarger, Stéphane, MD ~~D'Incan, Michel, Prof./MD~~ Mansard, Sandrine, MD	~~0~~

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
407	Thyss, Antoine, Prof./MD	Centre Antoine Lacassagne 33, avenue de Valombrose 06189 NICE Cedex 2, France	Peyrade, Frédéric, MD Mari, Verinoque, MD	5
411	Becker, Juergen C., Prof./MD	Klinik und Poliklinik für Hautkrankheiten Universitaetsklinikum Wuerzburg Josef-Schneider-Strasse 2 97080 Wuerzburg Germany	Eggert, Andreas, MD Frey, Lydia, MD Keller, Gunhild, MD Kürzinger, Natalie, MD Moosbauer, Stephanie, MD Papavassilis, Charis, MD Terheyden, Patrick, MD Weller, Karsten, MD Wieshuber, Christine, MD Wobser, Marion, MD	7
413	Vaubel, Julia, MD (nee Freise) Loquai, Carmen, MD Grabbe, Stephan, MD	Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie Universitaetsklinikum Essen Hufelandstr. 55 D-45122 Essen Germany	Esser, Stefan, MD Hoelzle, Katrin, MD Lehnen, Michaela, MD Loquai, Carmen, MD Voshege, Nadine, MD	12
~~414~~	~~Hauschild, Axel, Prof./MD~~	~~Universitaets-Hautklinik Universitaetsklinikum Schleswig-Holstein Campus Kiel Schittenhelmstr. 7 24105 Kiel Germany~~	~~Jahnke, Katharina, MD Kähler, Katharina, MD Kaiser, Dorothee, MD~~	~~0~~

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
~~415~~	~~Kaatz, Martin, MD~~	~~Klinik fuer Dermatologie und dermatologische Allergologie Klinikum der Friedrich-Schiller-Universitaet Jena Erfurter Strasse 35 07740 Jena Germany~~	~~Goetze, Steven, MD Koehler, Johannes, MD Preller, Anja, MD Roediger, Christiane, MD Schmidt, Ivonne, MD~~	~~0~~
416	Keilholz, Ulrich, Prof./MD	Charité - Universitaetsmedizin Berlin Campus Benjamin Franklin Medizinische Klinik III, Hematology, Oncology and Transfusion Medicine Hindenburgdamm 30 12200 Berlin Germany	Asemissen, Anne Marie, MD Busse, Antonia, MD Gabriel, Verena, MD Kiecker, Felix, MD Knödler, Maren, MD Na, Il-Kang, MD Trefzer, Uwe, MD Wilhelm, Tabea, MD Zimmerman, Kaja, MD	5
~~417~~	~~Mackensen, Andreas, Prof./MD~~	~~Abt. für Haematologie und Internistische Onkologie Klinikum der Universitaet Regensburg Franz-Josef-Strauß-Allee 11 93042 Regensburg Germany~~	~~Blank, Christian, MD Meidenbauer, Norbert, MD~~	~~0~~

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
418	Naeher, Helmut, Prof./MD	Universitaetsklinikum Heidelberg Hautklinik Voss Str. 2 69115 Heidelberg Germany	Becker, Maria, MD Bolz, Sven, MD Klein, Nina, MD Lonsdorf, Anke, MD Moser, Christian, MD Reidel, Rolf-Ulrich, MD Romer, Annette, MD Sandermann, Steffen, MD Scholz, Ina, MD Vago, Bernadette, MD Wiedemeyer, Katharina, MD	5
419	Peschel, Christian, Prof./MD	Klinikum rechts der Isar III. Medizinische Klinik und Poliklinik Technical University Munich Ismaninger Str. 22 81675 Munich Germany	Bernhard, Helga, MD Bogner, Christian, MD Gotze, Katharina, MD Graf, Nicolas Alexander, MD Kroenig, Holger, MD Meyer zum Buschenfelde, Christian, MD von Bubnoff, Nikolas, MD	10

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
420	Hassel, Jessica, MD Schadendorf, Dirk, Prof./MD	Universitaetsklinikum Mannheim gGmbH Hautklinik, Klinische Kooperationseinheit für Dermato-Onkologie Universitaet Heidelberg Theodor-Kutzer-Ufer 1 68135 Mannheim Germany	Booken, Dirk, MD Figl, Robert, MD Fink, Wolfram, MD Hassel, Jessica, MD Thoenke, Adina, MD Ugurel, Selma, MD Utikal, Jochen, MD Wurz, Judith, MD Zimmer, Lisa, MD	14
422	Welzel, Julia, MD	Klinik fuer Dermatologie und Allergologie Klinikum Augsburg Stenglinstr. 2 D-86156 Augsburg Germany	Kraemer, Kai-Uwe, MD Rothmund, Gabriele, MD Starz, Hans, MD von Ostini, Alexandra, MD	4
423	Garbe, Claus, Prof./MD	Universitaets-Hautklinik Sektion Dermatologische Onkologie Eberhard-Karls-Universitaet Tübingen Liebermeisterstr. 25 72076 Tübingen Germany	Eigentler, Thomas Kurt, MD Kamin, Anne, MD Pflugfelder, Annette Dorothee, MD Weide, Benjamin Matthias, MD	5
424	Schuler, Gerold, Prof./MD	Dermatologische Klinik mit Poliklinik Universitaetsklinikum Erlangen Hartmannstr. 14 91052 Erlangen Germany	Haendle, Ina, MD Kaempgen, Eckhart, Prof./MD Schmitt-Haendle, Matthias, MD Schuler-Thurner, Beatrice, MD	3

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
~~425~~	~~Schulte, Klaus-Werner, MD~~	~~Universitaetsklinikum Duesseldorf Hautklinik Moorenstr. 5 D-40225 Duesseldorf Germany~~	~~Drager, Heike, MD Reinerth, Gunter, MD Roller, Evelyn, MD~~	~~0~~
426	Keilholz, Ulrich, Prof./MD	Charité - Universitaetsmedizin Berlin Campus Benjamin Franklin Medizinische Klinik III, Hematology, Oncology and Transfusion Medicine Hindenburgdamm 30 12200 Berlin Germany	Asemissen, Anne Marie, MD Busse, Antonia, MD Gabriel, Verena, MD Kiecker, Felix, MD Knödler, Maren, MD Na, Il-Kang, MD Trefzer, Uwe, MD Wilhelm, Tabea, MD Zimmerman, Kaja, MD	7
431	Awada, Ahmad, MD	Institut Jules Bordet Dept of Medical Oncology Bd de Waterloo, 121 1000 Brussels Belgium	Caspers-Velu, Laure, MD Besse, Tatiana, MD D'Hondt, Véronique, MD Vereecken, Pierre, MD	3
~~432~~	~~Baurain, Jean-Francois, MD~~	~~Cliniques Universitaires Saint-Luc Dept of Medical Oncology Avenue Hippocrate 10 1200 Brussels Belgium~~	~~Humblet, Yves, MD Machiels, Jean-Pascal, MD~~	~~0~~

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
433	Cocquyt, Veronique, MD	University Hospital Ghent Dept Medical Oncology De Pintelaan 185 9000 Ghent Belgium	Denys, Hannelore, MD Rottey, Sylvie, MD Van Belle, Simon, Prof./MD	3
434	Kerger, Joseph, MD	Cliniques Universitaires UCL de Mont-Godinne Department of Haematology-Medical Oncology Avenue G. Therasse 1 5530 Yvoir Belgium	Jacquy, Caroline, MD Silvestre, Rose-Marie, MD	2
435	Thomas, Jose, MD	Universitaire Ziekenhuizen Leuven Dept of General Medical Oncology Herestraat 49 3000 Leuven Belgium	Clement, Paul M.J., MD Dumez, Herlinde, MD Schöffski, Patrick, Prof./MD Wildiers, Hans P.M.W., MD Wolter, Pascal, MD	7
436	Lienard, Danielle, MD Velu, Theirry, MD	Erasme Hospital, Free University of Brussels Medical Oncology Route de Lennik, 808 1070 Brussels Belgium	Gordower, Laurence, MD Laporte, Marianne, MD Lienard, Danielle, MD Luce, Sylvie, MD Nouwynck, Claire, MD Richard, Vincent, MD Myrto-Georgia, Trakatelli MD Vereecken, Pierre, MD	2

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
~~440~~	~~Berchem, Guy, MD~~	~~Centre Hospitalier de Luxembourg Hématologie-Cancérologie rue Barblé, 4 1210 Luxembourg Grand Duchy of Luxembourg~~	~~Dicato, Mario, Prof./MD Duhem, Caroline, MD Ries, Fernand, MD~~	~~0~~
441	Van den Eertwegh, A.J.W., MD	Vrije Universiteit Medical Centre Department of Medical Oncology De Boelelaan 1117 1081 HV Amsterdam The Netherlands	Boven, Epie, MD Buter, J., MD Gerritsen, W, MD Giaccone, G., Prof./MD Hoekman, K, MD Kuenen, B, MD van de Heilgenberg, S., MD	13
442	Haanen, J.B.A.G., MD	Antoni van Leeuwenhoek ziekenhuis- Nederlands Kankerinstituut Department of Medical Oncology Plesmanlaan 121 1066 CX Amsterdam The Netherlands	Blank, C., MD de Gast, G.C., MD	17

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
443	Jansen, R.L.H., MD	Academisch Ziekenhuis Maastricht Afdeling Hematologie-Oncologie P. Debeyelaan 25 6229 HX Maastricht The Netherlands	Hupperets, P.S.G.J., MD Lalisang, R.L., MD Pepels, M., MD Soetekauw, P., MD Te Sligte, K., MD Tjan-Heijnen, V., Prof./MD Werner, P., MD	4
447	Dummer, Reinhard, Prof./MD	Dermatologische Klinik Universitaetsspital Zuerich Gloriastr. 32 8091 Zuerich Switzerland	Baumann-Conzett, Katrin, MD Enderlin, Valérie, MD Goldinger, Simone, MD Heidecker, Barbara, MD Imhof, Laurence, MD Schad, Karin, MD Skalsky, Jeannine, MD	9
448	Michielin, Olivier, MD Voelter, Verena, MD	Centre Hospitalier Universitaire Vaudois Centre Pluridisciplinaire d'Oncologie BH06 - Rue du Bugnon 46 CH-1011 LAUSANNE Switzerland	Horn, Violeta, MD Leyvraz, Serge, Prof./MD Nay, Cristina, MD	2
451	Karolyi, Zsuzsanna, MD	Semmelweis Hospital Department of Dermatology Csabai kapu 9-11. H-3529 Miskolc Hungary	Lengyel, Eniko, MD	1

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
~~452~~	~~Kemeny, Lajos, Prof./MD~~	~~University of Szeged Albert Szent-Györgyi Medical and Pharmaceutical Center Department of Dermatology and Allergology Korányi fasor 6. 6720 Szeged Hungary~~	~~Gyulai, Rolland, MD Olah, Judit, MD~~	~~0~~
~~453~~	~~Gilde, Katalin, MD~~	~~National Institute of Oncology Department of Oncodermatology Rath Gyorgy u. 7-9. H-1122. Budapest Hungary~~	~~Banfalvi, Teodora, MD Borbola, Kinga, MD Fejos, Zsuzsanna, MD Liszkay, Gabriella, MD Papp, Andrea, MD~~	~~0~~
~~454~~	~~Hunyadi, Janos, Prof./MD~~	~~University of Debrecen Medical and Health Sciences Center Department of Dermatology Nagyerdei krt. 98. H-4012. Debrecen Hungary~~	~~Begany, Agnes, MD Emri, Gabriella, MD Gaspar, Krisztian, MD~~	~~0~~
~~471~~	~~Underhill, Craig, MD~~	~~Border Medical Oncology Murray Valley Private Hospital Nordsvan Drive Wodonga VIC 3690 Australia~~	~~Clarke, Kerrie, MD Steer, Christopher, MD~~	~~0~~

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
~~473~~	~~Hersey, Peter, Prof./MD~~	~~Oncology Immunology Unit David Maddison Building Corner of King and Watt Street Newcastle NSW 2305 Australia~~	~~None~~	~~0~~
~~474~~	~~Millward, Michael, Prof./MD~~	~~Sir Charles Gairdner Hospital Hospital Avenue Nedlands WA 6009 Australia~~	~~Buck, Martin, MD Byrne, Michael, MD Dewar, Joanna, MD van Hazel, Guy, MD Nowak, Anna, MD Powell, Alex, MD~~	~~0~~
~~478~~	~~Sabesan, Sabe, MD~~	~~Townsville Cancer Centre The Townsville Hospital 100 Angus Smith Drive Douglas QLD 4814 Australia~~	~~Forouzes, Bahram, MD~~	~~0~~
~~481~~	~~Alberts, Albert, MD~~	~~Wilgers Oncology Unit Denneboom Avenue Wilgers Extension 14 Pretoria, 0050, South Africa~~	~~Bouwer, Jacobus Everhardus, MD Rossouw, Maritha, MD~~	~~0~~

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
482	Cohen, Graham Lawrence, MD	Mary Potter Oncology Centre Little Company of Mary Hospital Totius Street, Groenkloof, 0181 South Africa	de Klerk, Era, MD Dreosti, Lydia, Prof. Kukard, Craig, MD Lombard, Janine Margaret, MD Slabber, Coenraad Frederik, MD Vorster, Ananda, MD	9
~~483~~	~~Malan, Jorn, MD~~	~~Eastern Cape Oncology Centre St Georges Hospital 40A Park Drive, Port Elizabeth, 6000 South Africa~~	~~Bonfils-Persson, Frank Harry, MD Jonas, Natalie Irene, MD Jones, Lee-Anne, MD Maart, Keith Ian, MD~~	~~0~~
484	Raats, Johannes Isaac, MD	GVI Oncology Clinical Trial Department 110 Panorama Medical Centre Hennie Winterbach Drive Panorama, 7506 South Africa	Dreyer, Andre Willer, MD du Toit, Johanna Sophia, MD Jacobs, Conrad, MD Malan, Tina-Marie, MD Nel, Redmund, MD Pienaar, Fredrieka Maria, MD Schneider-Waterberg, Elizabeth, MD Serfontein, Laura, MD Van der Merwe, Steven, MD	2
485	Vorobiof, Daniel Alberto, MD	Sandton Oncology Medical Research 159 Rivonia Road Morningside Sandton, 2199 South Africa	Bairstow, Sally, MD	3

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
~~486~~	~~Rapoport, Bernardo, MD~~	Medical Oncology Centre of Rosebank 129 Oxford Road Saxonwold, 2196 South Africa	~~Rodrigues, Sylvia, MD~~	~~0~~
491	Lima, Aline, MD	Santo Andre Diagnosticos e Tratamentos Rua das Bandeiras, 175 Santo Andre SP - Brazil 09090-780	Bassani, Antonio, MD Cardial, Caetano, MD Faulhaber, Amanda, MD	2
492	Buzaid, Antonio, MD Dzik, Carlos, MD	Sociedade Beneficente de Senhoras - Hospital Sirio Libanes Rua Dona Adma Jafet, 91 Sao Paulo - SP - Brazil 01308-050	Buzaid, Antonio, MD Costa, Frederico, MD Maluf, Fernando, MD Marques, Ricardo, MD Massumoto, Celso, MD	4
493	Barrios, Carlos, MD	Hospital Sao Lucas da PUCRS Av. Ipiranga 6690-4° Andar Porto Alegre-RS-Brazil-90610-000	Andrade, Helena, MD Costa, Fernanda, MD Neto, Antonio, MD Viola, Fabiana, MD	7
~~494~~	~~Cabral, Claudio, MD~~	Hospital Araujo Jorge da Associação de Combate ao Cancer em Goias Rua 239, 181 Setor Universitario 74605-070 Goiania-GO-Brazil	Filho, Roberto, MD Giroto, Gustavo, MD ~~Gonçalves, Márcia, MD~~ Jendiroba, David, MD Queiroz, Renata, MD	~~0~~

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
495	Schwartsmann, Gilberto, MD	Fundação Central Sul-Americana para o Desenvolvimento de Drogas Anticancer-SOAD Hospital de Clínicas de Porto Alegre R. Ramiro Barcelos, 2350, 3 leste, sala 399 90035-003 Porto Alegre-RS-Brazil	Andrade, Helena, MD Cassol, Lina, MD Lima, Cleber, MD	2
496	Hohmann, Jason, MD	Fundação Pio XII - Hospital de Cancer de Barretos Rua Antenor Duarte Villela, 1331 Barretos - SP - Brazil 14784-400	Capuchinho, Isabel, MD Motta, Tatiane, MD	1
497	Liberatti, Mario, MD	Pro Onco Centro Tratamento Oncológico Avenida Adhemar Pereira de Barros, 679 Londrina -PR-Brazil 86050-190	Herrera, Ana, MD	8
498	Federico, Miriam, MD, PhD	Instituto do Cancer de Sao Paulo- Octavio Frias de Oliveria-ICSP Av. Doutor Arnaldo, 251, 5 ° andar ZIP CODE: 01246-000 Sao Paulo/SP- Brazil	Barros, Laryssa, MD Bassani, Antonio, MD Carelli, Guareide, MD de Castro, Gilberto, MD Diz, Maria, MD Folgueira, Maria, MD Snitcovsky, Igor, MD, PhD	3
500	Segalla, Jose, MD	Fundação Hospital Amaral Carvalho/Hemonúcleo de Jaú Rua Dona Silvéria, 150 Jaú-SP- Brazil 17210-080	Andrade, Ana Cléa, MD Beato, Carlos, MD Coradazzi, Ana, MD de Oliveira, Claudia Teresa, MD Ismael, Gustavo, MD Urakawa, Paula, MD	8

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
~~506~~	~~Blajman, Cesar Raul, MD~~	~~ISIS Clínica Especializada Urquiza 3077 - Santa Fé (S3000FFU) Provincia de Santa Fé, Argentina~~	~~Calafell, María Gabriela, MD~~	~~0~~
508	Lerzo, Guillermo Luis, MD	Hospital Municipal de Oncología Maria Curie Patricias Argentinas 750 - (C1405BWU) Buenos Aires, Argentina	Campos, Claudio Andrés, MD Dos Reis August, Alba Lopes, MD Gennari, Luciana, MD Lescano, Jorge, MD Ranone, Viviana Aida, MD	1
~~509~~	~~Palazzo, Emilio, MD~~	~~Hospital Privado Centro Médico de Córdoba S.A. Naciones Unidas 346 - (X5016KEH) Provincia de Córdoba, Argentina~~	~~Bazan, Fernando Felix, MD Borello, Adriana Elizabeth, MD Hollmann, Carlos Hernán, MD Sanchez, Natalia Martinez, MD Soria, Andrea Gabriela, MD~~	~~0~~
510	Chacón, Matías, MD	Instituto Médico Especializado Alexander Fleming Cramer 1180 - (C1426ANZ) Buenos Aires, Argentina	Costanzo, María Victoria, MD Nasroulah, Federico, MD	1
511	Santos, Ricardo Luis, MD	Hospital Militar Central Luis María Campos 726 -(C1426BOS) Buenos Aires, Argentina	Batagelj, Emilio José, MD Lehmann, Augustin, MD Torres, Alejandra María, MD	3

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
~~513~~	~~Silva, Carlos Alberto, MD~~	~~Hospital Británico de Buenos Aires Perdriel 74 - (C1280AEB) Buenos Aires, Argentina~~	~~D`Annunzio, Julieta Mabel, MD Korbenfeld, Ernesto Pablo, MD Quero, Luciana Bella, MD Rubio, Gonzalo Javier, MD Vera, Karina Alejandra, MD~~	~~0~~
514	Koliren, Leonardo, MD	Hospital General de Agudos Carlos G. Durand Av. Díaz Velez 5044 - (C1405DCS) Buenos Aires, Argentina	Bianconi, María Inés, MD Jankilevich, Gustavo, MD O`Leary, Karina Gabriela, MD Otero, Silvina Susana, MD	6
~~515~~	~~Alvarez, Pedro Eugenio, MD~~	~~Instituto Medico Platense Boulevard 51 N°315 - La Plata (1900) Buenos Aires, Argentina~~	~~Chaparro, Jorge Gustavo, MD Fasce, Hebe Margot, MD~~	~~0~~
~~521~~	~~Gamargo, Claudia, MD~~	~~Hospital Barros Luco Trudeau- CDT Gran Avenida 3204 Santiago, Chile~~	~~Caglevic Medina, Christian Lorenzo MD~~	~~0~~
522	Gonzalez-Mella, Pablo, MD	Clinica Reñaca Anabaena 336, Reñaca Viña del Mar, Chile	Fort , Eugenia de las Nives Loredo, MD Mancilla, Luis Roberto Alvarado, MD Prieto, Marielisa Leon, MD Rios, German Federico Adolfo Rey , MD	1

Appendix A.5: List of Investigators

Site No.	Primary Investigator	Center and Address	Subinvestigators and Responsible Medical Personnel	Enrollment
524	Boghikian, Pamela Victoria Salman, MD	Fundacion Arturo Lopez Perez Av. Rancagua 878 Providencia Santiago, Chile	Majilis Luquer, Alejandro MD Vogel Wenireich, Conrado Max Reinhold MD Kleinman Singer, Sergio Enrique MD	2
~~525~~	~~Yanez, Manuel, MD~~	~~Clinica Davila Recoleta 464, Recoleta Santiago, Chile~~	~~Rojas Romero, Hernan Humberto MD~~	~~0~~
526	Harbst, Hans, MD	Instituto Nacional del Cancer Avda., Profesor Zañartu 1010 Santiago, Chile	Conejeros Lopez, Roque Antonio MD Muller, Bettina MD Villanueva Olivares, Luis Marcello MD	4